

ADVANCED REVIEW

Synthetic cells in biomedical applications

Wakana Sato¹  | Tomasz Zajkowski^{2,3,4}  | Felix Moser⁵ |
Katarzyna P. Adamala¹ 

¹Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, Minnesota, USA

²Centre of New Technologies, University of Warsaw, Warsaw, Poland

³USRA at NASA Ames Research Center, Mountain View, California, USA

⁴Blue Marble Space Institute of Science, Seattle, Washington, USA

⁵Synlife, Inc., Cambridge, Massachusetts, USA

Correspondence

Felix Moser, Synlife, Inc., One Kendall Square Suite B4401, Cambridge, MA 20139, USA.

Email: felix@synlifebio.com

Katarzyna P. Adamala, Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, MN 55455, USA.

Email: kadamala@umn.edu

Funding information

National Institutes of Health, Grant/Award Number: 5R01MH114031-02; National Science Foundation, Grant/Award Numbers: 1840301, 1844313; John Templeton Foundation, Grant/Award Number: 61184

Edited by: Julian Vastl, Managing Editor and Nils Walter, Co-Editor-in-Chief

Abstract

Synthetic cells are engineered vesicles that can mimic one or more salient features of life. These features include directed localization, sense-and-respond behavior, gene expression, metabolism, and high stability. In nanomedicine, many of these features are desirable capabilities of drug delivery vehicles but are difficult to engineer. In this focus article, we discuss where synthetic cells offer unique advantages over nanoparticle and living cell therapies. We review progress in the engineering of the above life-like behaviors and how they are deployed in nanomedicine. Finally, we assess key challenges synthetic cells face before being deployed as drugs and suggest ways to overcome these challenges.

This article is categorized under:

Therapeutic Approaches and Drug Discovery > Emerging Technologies
Biology-Inspired Nanomaterials > Lipid-Based Structures

KEYWORDS

synthetic biology, synthetic cells

1 | INTRODUCTION

Living cells offer many impressive capabilities that nanoparticle engineers often seek to imitate. These include directed localization (e.g., chemotaxis), sense-and-respond behavior, gene expression, metabolism, and high chemical and serum stability. Recent years have seen considerable advances in the bottom-up engineering of synthetic cells (SCs). Though several aspects of this technology are still in their formative stages, this field has made substantial headway into the realm of clinical applications.

Wakana Sato Tomasz Zajkowski authors contributed equally to this work.

The phrase “synthetic cell” has been used widely and requires disambiguation. Here, we use “synthetic cell” to mean an aqueous compartment bounded by either a polymer or lipid membrane that comprises molecular machinery sufficient to mimic one or more of the above features of living cells. Moreover, in the context of medicine, these features can induce desirable therapeutic outcomes. SCs can range from 100 nm to 10's of μm in size. However, most synthetic cell studies work at scales $>1 \mu\text{m}$ due to the technical difficulty of generating nano-sized vesicles. SCs can be built from defined, synthetic components (“bottom-up”) or a combination of synthetic and cell-derived components (“semi-synthetic”). Here, we consider “top-down” engineering or harnessing of extant living cells a distinct technology and beyond the scope of this review.

The above definition of SCs emphasizes the compartmentalization of an aqueous interior. This is because physical segregation of an aqueous core enables many of the functions of cellular life, including aqueous biochemistry involved in everything from gene expression to enzymatic reactions. The presence of a distinct amphiphilic membrane structure is also key, as it enables signal transduction, selective transport, and the anchoring of functional moieties on and within the membrane. The aqueous interior and amphiphilic membrane distinguishes SCs from solid polymer nanoparticles, lipid nanoparticles and micelles with hydrophobic interiors, which cannot perform many of these functions that are critical to living system.

In terms of complexity, SCs can be thought of as an intermediate between passive nanoparticle drug delivery systems (e.g., liposomes) and engineered living cell therapies (e.g., Chimeric Antigen Receptor T cells or synthetic beta cells for diabetes treatment [Chen et al., 2018]). Compared to nanoparticles, SCs generally have many more unique components. This greater complexity makes them more capable than nanoparticles but also more difficult to manufacture and control. Compared to living cells, SCs are much simpler and well-defined. Despite the incredible progress of modern cell biology, cells are still in large part black boxes—they are incompletely understood and therefore inherently unpredictable, especially when faced with the wide diversity of environments in human physiology. Hence, engineered living cells present inherent risks when deployed as therapeutics. SCs, on the other hand, are assembled bottom-up from known components and are therefore better defined and more predictable. Additionally, SCs will not replicate (unless they are programmed to). Therefore, SCs can offer considerable safety advantages over living cells.

SCs can also perform tasks that living cells cannot (Figure 1). For example, SCs can utilize non-natural and toxic molecules to a degree not possible in extant living cells (Martin et al., 2018). Non-natural amino acids have been shown to endow proteins with valuable properties such as longer half-lives and enabling biochemistry (H.-N. Chang et al., 2015; Gao et al., 2019). Highly toxic molecules that would otherwise kill living cells can also be produced with *in vitro* transcription/translation (IVTT) systems encapsulated in SCs (Dondapati et al., 2018; Orth et al., 2011; Salehi et al., 2016). Composing SCs of other exotic chemistry can therefore endow them with unique advantages in terms of stability as well as the functions they can enact inside the body.

Additionally, while manufacturing of SCs presents its own challenges (more below), it promises certain advantages over the manufacturing of engineered living cell therapies. Autologous cell therapies currently require extensive handling. The process of purifying, engineering, amplifying, and re-administering autologous cell therapies makes their manufacture extraordinarily expensive and time consuming (R. K. Iyer et al., 2018). Synthetic cells, on the other hand, could in theory be generated at centralized facilities, lyophilized or otherwise preserved, and shipped to hospitals, much like current biotherapeutics. Their manufacturing is scalable via microfluidics and can be generalized across different indications and compositions. At the same time, their manufacture at a smaller scale would still allow customization for personalized medicine.

Here, we review how the capabilities of synthetic cells can be leveraged for therapeutic effect. First, we describe the structure and components of SCs and review some of the manufacturing approaches developed to date. We then discuss how the life-like processes that can be engineered in synthetic cells—directed localization, sense and respond behavior, gene expression, metabolism—can offer unique therapeutic strategies. Finally, we discuss both the technical and regulatory hurdles that challenge the development of SC therapeutics.

2 | COMPOSITION AND STRUCTURE

Synthetic cells mainly comprise a membrane and an internal payload. In the context of drug delivery, the membrane has several key functions. First, it protects the payload from destabilizing factors in the external environment. Second, it prevents the payload from getting out too quickly and triggering physiological responses (e.g., anaphylaxis). Third, it concentrates the payload in the interior, enabling critical biochemistry or the delivery of the payload to its target at a




FIGURE 1 Comparison of synthetic cells to other drug delivery systems. Synthetic cells tend to fall between liposomes and living cells in terms of complexity. Their capabilities extend beyond those of liposomes but cannot match the sustained, nuanced behaviors of living cells. This relative simplicity also endows them with advantages, such as complete programmability and zero risk of uncontrolled replication

high concentration. Last, the membrane itself allows for the anchoring of membrane proteins or other moieties that further stabilize or functionalize the SC.

The composition of the membrane is critical to the SC's stability and function and must be carefully considered. The membrane may comprise phospholipids, proteins (Huang et al., 2014), polymers (Kuiper et al., 2008), peptides (Fatouros et al., 2014), colloids (S. Sun et al., 2016), virus membrane, or capsids (H. Liu, Zhigang, et al., 2015; Y. Wang, Uchida, et al., 2020), or other amphiphilic molecules as well as small molecules such as cholesterol that have a stabilizing effect (Briuglia et al., 2015). As such, the membrane composition can be tuned to endow the SC with varying stability in different environments. This, in effect, enables the SC to “sense” the environment (see below). The composition of the membrane can also affect the function of embedded proteins (Elmore & Dougherty, 2003). During formation of liposomes, the inner and outer leaflets can be produced separately, making their composition unique (de Matos et al., 2019; Doktorova et al., 2018). This enables unique functions to be incorporated at the interior and exterior of the membrane.

Inside a patient, SCs experience diverse, challenging environments. Once injected, a unique protein corona will form around the SC (Francia et al., 2020). The composition of the protein corona is dynamic and depends on many variables, including the membrane composition, charge, zeta potential, and size, among others (Baimanov et al., 2019; Giulimondi et al., 2019; Pattipeiluhu et al., 2020). Undecorated SCs are typically recognized as nonself and cleared by the reticuloendothelial system (RES), mainly in the liver and spleen (Sercombe et al., 2015). Once opsonized, the SCs are recognized by macrophages and cleared via phagocytosis (Sercombe et al., 2015). SCs can also be damaged via enzyme activity, which further reduces their half-life. The use of PEG to shield the outside of the liposome from the surrounding matrix has been a highly successful strategy in lengthening nanoparticle half-lives in vivo (Maruyama et al., 1992; Photos et al., 2003). Many strategies have been developed to improve on current shielding effects (Boyer & Zasadzinski, 2007; Gulati et al., 2018; He et al., 2019).

The interior of the SC contains the payload, which can be drug or aqueous solutions that further endow the SC with function. In the simplest case, the compartment houses only a small molecule drug to be delivered to the site of action. In one of the most complex cases, the compartment houses an IVTT reaction mixture that can generate genetically encoded RNA or protein (Silverman et al., 2020). In some cases, SCs can house entire particles, vesicles (N.-N. Deng et al., 2017), or condensates (S. Liu, Zhang, et al., 2020; Niederholtmeyer et al., 2018) that can further endow the SC with functions such as sensing, metabolism, (Leduc et al., 2007) and movements (more below; Siton-Mendelson & Bernheim-Groswasser, 2016).

A variety of methods have been developed to manufacture synthetic cells. These include thin-film hydration (H. Zhang, 2017), reverse emulsion (Huang et al., 2013; Pautot et al., 2003; Thompson et al., 2015), electroemulsion (Angelova & Dimitrov, 1986), and others (Fatouros et al., 2014; Y. Hu & Qiu, 2019; H. Liu, Zhigang, et al., 2015). Recently, microfluidic platforms and other techniques have been developed to improve the efficiency, speed, and reliability of SC generation: electroformation and hydration (Girard et al., 2004), extrusion (Dittrich et al., 2006), hydrodynamic focusing (Jahn et al., 2004), pulsed jetting (Funakoshi et al., 2007; Gotanda et al., 2018; Kamiya et al., 2016), double emulsion templating (Shum et al., 2008), transient membrane ejection (Matosevic & Paegel, 2011), droplet emulsion transfer (Ota et al., 2009), reverse emulsion (cDICE; Abkarian et al., 2011), droplet-supported dGUV (Haller et al., 2018; Weiss et al., 2018), octanol-assisted liposome assembly (Deshpande et al., 2016), wedge splitting (Deshpande et al., 2018), and toroidal mixing (Webb et al., 2020). This rapid innovation suggests that many hurdles to microfluidic manufacturing may soon be overcome, which could prove catalytic to the field (Shah et al., 2020). The synthetic cells that result from these processes tend to range from 500 nm to several tens of microns in size. The larger the particle, the faster it is cleared from the body, so therapeutic nanoparticles are generally made as small as possible, on the order of 10–100 nm (Hoshyar et al., 2016). The more complicated the SC composition, the more difficult the manufacturing process becomes and places considerable technical and cost constraints on SC therapeutics.

3 | APPLICATIONS OF SYNTHETIC CELLS

How synthetic cells are utilized in nanomedicine is determined by their capabilities (Figure 2). Life-like capabilities that can be engineered include directed localization, sense-and-respond behavior, gene expression, metabolism, and high in vivo stability. Applications of these properties range from diagnostics to therapeutics.




FIGURE 2 Life-like functions of synthetic cells in nanomedicine. Synthetic cells are engineered with various chemical tools to mimic one or more functions of living cells. The physical properties of the SCs affect both their stability and localization through the enhanced permeability and retention effect

3.1 | Directed localization

A key strategy of living things is to move toward resources that benefit them. Similarly, there is great value in engineering synthetic cells that move to or localize at a target site. This physically concentrates SC's activity at the target and reduces off-target toxicity. Targeted localization can be accomplished either actively (by energy-consuming movement) or passively (by increasing their affinity to the target tissue).

Significant progress has been made in endowing SCs with active chemotactic systems. While liposomes have been used to study natural systems of cell locomotion, these systems have proven difficult to employ due to their complexity (Pontani et al., 2009; Siton-Mendelson & Bernheim-Groswasser, 2016). Recently, relatively simple synthetic systems that leverage biophysical principles have provided more traction (Gentile et al., 2020). Conjugation of enzymes to the surface of liposomes has been shown to endow them with the ability to move up or even down a pH or metabolite gradient (Ghosh et al., 2019; Hortelão et al., 2020; Somasundar et al., 2019). This strategy has also proven effective in polymersomes (J. Wang, Jelle Toebes, et al., 2020). Battaglia and colleagues created polymersomes with asymmetrically thick membranes that use encapsulated enzymes to generate a motor force (Joseph et al., 2017). Another type of polymersome used a platinum nanoparticle to catalyze peroxide oxidation to chemotax toward neutrophils (Peng et al., 2015). Other mechanisms for directed chemotaxis include the conjugation of complementary DNA oligomers or light-activated protein binders to a surface (Bartelt et al., 2018; Pan et al., 2019). However, such strategies are more difficult to implement *in vivo*. Another method for directed localization is the conjugation of nanoparticles to living cells as “cellular backpacks” (Jones et al., 2017; Klyachko et al., 2017; Layek et al., 2018; Xie et al., 2017), but this does not require life-like behavior from the nanoparticle itself.

Passive targeting can be accomplished by increasing the affinity of SCs to the target tissue while relying on diffusion and circulation to do the work of carrying them to the tissue. In these cases, the surface of SCs can be modified with polymers, protein ligands, or antibodies that increase their targeting specificity (De Leo et al., 2018; J. Cao et al., 2018; Kim et al., 2019). When multiple targeting moieties are used, the specificity of the targeting increases (Gray et al., 2013; P. Guo et al., 2019; Nikkhai et al., 2018; S. Oliveira et al., 2010; Qu et al., 2014). While implementing these strategies, engineers must carefully consider the conjugation chemistry and orientation of the targeting molecules.

The physical properties of synthetic cells can also passively target them to specific tissues. For example, the small size of nanoparticles tends to concentrate them in tissues in which the enhanced permeability and retention (EPR) effect is observed, such as tumors and inflamed or otherwise damaged tissue (Allen & Cullis, 2013; Lammers et al., 2012; Lobatto et al., 2015; van den Hoven et al., 2011). However, recent work has shown that the EPR effect is dynamic and depends greatly on the composition and structure of the tissue (Danhier, 2016; J. Fang et al., 2020; Natfji et al., 2017). As another example, the strong positive charge of cationic lipid nanoparticles leads them to be taken up by the liver at high efficiencies (Witzigmann et al., 2020). This has made cationic lipid nanoparticles excellent delivery vehicles for nucleic acid-based gene therapies such as Patisiran (Adams et al., 2018).

Another approach to achieve localization is to coat nanoparticles with natural membranes (de Ávila et al., 2018). For example, nanoparticles decorated with red blood cells (RBCs) membranes can target macrophages (Wan et al., 2018). To target cancer cells, nanoparticles can be decorated with cell membranes of platelets (Sarkar et al., 2013). Platelet membranes can be additionally labeled with anti-CD22 monoclonal antibodies to precisely deliver drugs to tumor cells (Q. Hu et al., 2015; P. Xu et al., 2017). As an alternative anti-cancer approach, one can use cancer cell membranes to coat nanoparticles that will be presented to antigen-presenting cells and promote anticancer immune response (R. H. Fang et al., 2014).

3.2 | Sense and respond

Living organisms can sense key environmental cues and subsequently respond with the appropriate action. Such seemingly “smart” behaviors are key to survival and are a highly desirable function in nanomedicines for several reasons. First, they enable more precise delivery to target tissues. Second, they enable more “analog” responses in which the output can be titrated to the strength of the input signal, thereby avoiding undue toxicity in neighboring tissue. The landscape of such “smart” sensing in vesicles has been extensively reviewed elsewhere (Abraham et al., 2018; Leduc et al., 2007; Majumder & Minko, 2020; Torchilin, 2014).

Sense-and-response functions can be facilitated directly via changes in SC membrane structure. Membranes have been composed of molecules sensitive to temperature (Jose et al., 2019; F. Liu, Kozlovskaya, et al., 2015; Needham

et al., 2000; Ta et al., 2014; Tagami et al., 2011; Xi et al., 2020; Yatvin et al., 1978), light (Carter et al., 2014; Enzian et al., 2020; D. Luo et al., 2016; Miranda & Lovell, 2016; Peyret et al., 2017), magnetism (Amstad et al., 2011; Babincová et al., 2002; Geilich et al., 2017; H. Guo et al., 2015; H. Oliveira et al., 2013), acoustics (Z. Deng et al., 2016; Rwei et al., 2017; Shekhar et al., 2017), pH (Aghdam et al., 2019; De Leo et al., 2018; Naziris et al., 2017), redox states (Chi et al., 2017; Mirhadi et al., 2020; X. Yin et al., 2017), and enzymes (Haas et al., 2015; Thamphiwatana et al., 2014). By combining these materials, the membrane can sometimes be made sensitive to multiple types of stimuli (S. Feng et al., 2019; Tran et al., 2017), enabling even more precise targeting. The major limitation of these materials is that few respond to the specific molecules of interest, such as certain cell surface receptors or cancer metabolites. For this, more specific sensors such as protein receptors are required.

Sensing can also be accomplished by membrane-embedded amphiphiles or proteins that are sensitive to specific molecules or conditions. These can transduce detected signals into the interior of the SC through various mechanisms (Langton, 2020). Protein and peptide pores that respond to osmotic pressure, heat, pH, and electrical potential by creating selective and nonselective pores have been shown to work in liposomes (Aimon et al., 2011; Garamella et al., 2019; Kisovec et al., 2017; Kreir et al., 2008; Louhivuori et al., 2010; Yanagisawa et al., 2011). One group developed a membrane-spanning amphiphile that responds to changes in pH or protein unbinding by localizing at the interior leaflet of the liposome and inducing catalysis that results in the release of drug (Ding et al., 2019; Langton et al., 2017). Several bacterial 2-component systems (Ravikumar et al., 2017) have been functionally reconstituted in liposomes (Ito et al., 2009; Jung et al., 1997; Pflüger et al., 2018; Sanowar & Le Moual, 2005), though none of them have been used to induce downstream protein production. Additionally, few other natural or engineered protein transducers (e.g., the SynNotch receptor; Morsut et al., 2016) have been successfully tested in synthetic cells. This speaks to the sensitivity and complexity of many membrane-bound protein transduction systems and the difficulty with which they can be implemented in synthetic systems.

Another strategy is to embed nonspecific, permanently open pores into the membrane to enable passage of small molecule signals that then stimulate activity inside the SC. To that end, *Staphylococcus aureus* α -hemolysin has become a favorite tool for synthetic cell engineers due to its ability to spontaneously insert into a wide diversity of membranes and form nonspecific pores. This has been used to allow nutrients (Noireaux & Libchaber, 2004), chemical inducers (e.g., IPTG; Lentini et al., 2014), and other small molecules (Soga et al., 2020; Wu et al., 2011) to traffic the SC. Furthermore, SNAREs and DNA oligos have been used to facilitate SC fusions (Schuette et al., 2004; W. Xu et al., 2015) and thereby deliver molecular messengers into the interior of the target SC. Once inside the SC, these messengers can then induce catalysis or even protein production via gene expression.

Transcription factors, RNA riboswitches, and enzymes can also act as sensors inside the SC compartment. These sensors are limited to sensing the interior of the SC, so only molecules that can pass through the membrane or pore can be detected. Enzymes will detect their substrates, and the resulting reactions can change the ambient conditions, such as the pH (Peters et al., 2015). Various transcription factors and riboswitches that are sensitive to the presence of diverse small molecules (Dwidar et al., 2019; X. Liu, Silverman, et al., 2020; Salehi et al., 2017; L. Zhang, Guo, et al., 2020) and even light (Schroeder et al., 2012; P. Zhang, Yang, et al., 2020) can be used to control transcription and translation in SCs (see below). Combining sensor signals into transcriptional logic can enable powerful programming of Boolean behaviors (Adamala et al., 2017; S. Iyer et al., 2013; Shis et al., 2014). Communication between SCs and natural living cells has also been engineered and can give rise to complex interactions between synthetic and natural populations (Lentini et al., 2014, 2017). Furthermore, the communication that results from mass exchange and sensing among SCs enables the formation of complex multicellular “synthetic tissue” (Adamala et al., 2017; Aufinger & Simmel, 2018; Ding et al., 2019; Niederholtmeyer et al., 2018; Schwarz-Schilling et al., 2016; T.-Y. D. Tang et al., 2018; Toda et al., 2018; Villar et al., 2013). Transcriptional and translational responses to chemicals, however, are relatively slow compared to other sensing mechanisms. To program rapid responses such as those needed for a SC-based bionic jellyfish (Nawroth et al., 2012), electromechanical sensors and actuators still need to be developed.

3.3 | Gene expression

Another powerful capability of synthetic cells is their ability to express genes. Producing protein or small molecules in situ is advantageous in drug delivery when the drug is unstable, needs to be titrated or is so reactive that it would kill living cells. Through the action of encapsulated IVTT reaction mixture, SCs can produce RNA, proteins, or even small molecule drugs in situ. For this, nucleic acids encoding the desired gene must be co-encapsulated. IVTT reaction mixtures may include purified cell extract (Kwon & Jewett, 2015; Z. Z. Sun et al., 2013) or defined mixtures of recombinant

protein such as the PURE system (Y. Shimizu et al., 2001; Y. Shimizu & Ueda, 2010; Lavickova & Maerkl, 2019). Gene expression can be induced when a triggering signal is sensed (see above). RNA that is produced could serve as a diagnostic signal that can be detected by sequencing RNA extracted from whole blood (Pös et al., 2018). Translated proteins can be enzymes that together comprise a metabolic pathway that generates a small molecule drug (Dudley et al., 2016; Grubbe et al., 2020). SCs can also synthesize membrane proteins that will spontaneously insert into membranes and act as uptake signals to target cells. (Kaneda et al., 2009; Lu et al., 2019).

Previously, in situ protein production could only be accomplished by living cells. These were delivered into the body encapsulated in polymer membranes, where they could survive a long time while ameliorating chronic conditions such as diabetes (Calafiore et al., 1999; de Vos et al., 2002; Lim & Sun, 1980; Soon-Shiong et al., 1994; Y. Sun et al., 1996), neurological diseases (Bloch et al., 2004), hemophilia (Basic et al., 1996), or cancer (Löhr et al., 2001) and are reviewed elsewhere (T. M. S. Chang, 2005). Recent development of synthetic cells that encapsulate IVTT reactions offers an alternative approach to encapsulated whole cells. Schroeder and colleagues pioneered SC therapy by demonstrating that liposomes containing IVTT could be used to synthesize anti-cancer proteins inside tumors. In this work, they showed that synthetic cells producing *Pseudomonas* exotoxin A killed most cancer cells in culture and caused robust apoptosis when injected into 4 T1 tumors in mice (Krinsky et al., 2018).

Beyond its utility in direct therapeutic intervention, cell-free gene expressions has enabled other biomedical technologies and novel research tools. For instance, the high stability of freeze-dried IVTT reactions has enabled the development of on-demand biotherapeutic manufacturing platforms (Adiga et al., 2018; Adiga et al., 2020; Jaroentomechai et al., 2018; Pardee et al., 2016). Another example is liposome display, a technology that uniquely enables in vitro selection and directed evolution of protein pores (Fujii et al., 2014; Uyeda et al., 2016). Membrane-bound IVTT protein production can also control the orientation of integral membrane proteins (Ando et al., 2018; Ohta et al., 2016). Challenges these technologies still face include relatively low titers of protein produced, reproduction of critical post-translational modifications, and the limitations on controlling the insertion and orientation of membrane proteins. Nonetheless, due to the close ties between the fields of cell-free biochemistry and synthetic cell engineering, each will doubtless benefit from the other's continued advancement.

3.4 | Metabolism

Living cells maintain their functions through active metabolism. This allows them to act against entropy repeatedly or continuously over extended periods of time, a behavior that is challenging to engineer in nanoparticle drug delivery systems. SCs, however, can be loaded with complex biochemistry that can mimic many of the metabolic processes that living cells perform. These include production of energy molecules such as ATP, the regeneration of essential cofactors, or chemical transformation of target metabolites. The value of this is both to sustain the therapeutic function of the SC as well as directly metabolize toxic metabolites.

By actively generating ATP or other energy molecules, SCs can maintain a sustained response instead of generating only a short burst of activity from the ATP encapsulated during production. Several different approaches have been taken to endow SCs with the ability to generate ATP. A common strategy is to create a proton gradient that can then be used by ATP synthase to drive ATP production. To generate the proton gradient, light-activated bacteriorhodopsin (Z. Chen et al., 2019; Choi & Montemagno, 2005; Dhir et al., 2018) or other proton pumping systems (Altamura et al., n.d.; Cladera et al., 1996; X. Feng et al., 2016; Steinberg-Yfrach et al., 1998) can be embedded in the membrane. The resulting light-dependent ATP synthesis can then drive IVTT protein production (Berhanu et al., 2019) or other ATP-dependent processes. Though this approach has been fruitful, it is challenging to implement in vivo because light only penetrates a few millimeters into the skin (Sabino et al., 2016). Instead, ATP synthesis can be driven via catabolic chemistry on ambient energy-rich molecules (Biner et al., 2020; Calhoun & Swartz, 2005; Caschera & Noireaux, 2015; Jewett & Swartz, 2004). The feedstocks for these pathways are also substantially cheaper than the high-energy molecules used in some batch reactions.

Regeneration of cofactors such as nicotinamide adenine dinucleotide phosphate is often essential to maintain biochemical reactions. This can be accomplished by encapsulating enzymes that catalyze the regenerating reaction (Meeuwissen et al., 2011). Hirst and colleagues recently demonstrated sustained ATP synthesis by coupling ATP synthase to NADH oxidation (Biner et al., 2020). Integrating novel ways to import or regenerate cofactors and other reagents is critical for longer sustained reactions in synthetic cells.

Chemically transforming metabolites can provide vital therapeutic benefits. Vesicles that contain enzymes have been developed for therapeutic application since the 1960s. Seminal work by Thomas Chang demonstrated that compartmentalized enzymes could provide therapeutic effects in animals lacking normal enzyme activity (T. M. S. Chang & Poznansky, 1968). Since then, therapeutic encapsulations of urease (Cattaneo & Chang, 1991; Gu & Chang, 1990; Lvov et al., 2001; Miele et al., 2020), catalase (Shi et al., 2020; R. Zhang et al., 2017), superoxide dismutase (Niesman et al., 1997; Riedl et al., 2005; Shazeeb et al., 2014), β -galactosidase (Rao et al., 1994), bacterial DNA repair enzymes (Berardesca et al., 2012; D. Yarosh et al., 1996; D. B. Yarosh et al., 2019), alcohol oxidases (Pratsinis et al., 2017; C. Lizano et al., 1998; Whitmire et al., 1991), glucose oxidase (S. Liu, Zhang, et al., 2020) among others, have opened doors to novel therapies. Many of these formulations aim to remove membrane-permeable metabolites from the body. Pratsinis et al. employed liposomes bearing either alcohol oxidase or catalase in their membranes in peritoneal dialysis to remove ethanol from the blood of rats (Pratsinis et al., 2017). This work follows older efforts in which alcohol dehydrogenase and aldehyde dehydrogenase are encapsulated together to break down ethanol *in vivo*. In these systems, another enzyme (e.g., malate dehydrogenase) is used to regenerate the NAD⁺ cofactor required to maintain the oxidation reaction, highlighting the importance of cofactor regeneration to maintaining high catabolic rates (Campbell & Chang, 1978; T. M. S. Chang, 1987; Carmen Lizano et al., 2001).

Encapsulated enzymes provide value to an impressive diversity of indications. A recent clinically tested example include Lipoxysan, a transdermal liposomal encapsulation of superoxide dismutase, which was recently tested in Peyronie's disease in Phase 2 clinical trials (Riedl et al., 2005). Mann and colleagues demonstrated that complex assemblies of glucose oxidase-containing coacervate and hemoglobin-containing RBC-derived membranes were able to generate nitric oxide *in vivo*, inducing vasodilation (S. Liu, Zhang, et al., 2020). An example in which SCs serve to aid in diagnosis is in the work by Molina and colleagues. In this work, the authors generated different SCs containing mixtures of three or more different enzymes. Based on the metabolites present, SCs would generate different colored products. Incubating these SCs in urine aided in the diagnosis of prediabetic states in patients (Courbet et al., 2018).

Multilamellar liposomes, vesosomes, and different species of liposomes can work together to control reactions. Incompatible enzymes can be separated in defined compartments allowing the spatial organization and segregation of the multistep tandem reaction (Klermund et al., 2017). Different liposomes containing varied enzymes can be connected via α -hemolysis channels. Polymer SCs containing two distinct populations of enzyme-encapsulating vesicles have been demonstrated to function inside living cells (Godoy-Gallardo et al., 2017). To prevent the deactivation of catalysts in water or avoid unwanted cross-reactions, catalysts are often site-isolated in nanopockets or separately stored in compartments. These examples show that control of the localization of enzymes within an SC can be as valuable to the SCs function as the enzyme activity itself.

3.5 | High stability

One of the most desirable characteristics of living cells is their ability to remain intact in the blood for long periods of time. Nanoparticles, on the other hand, are typically less stable and are rapidly cleared by the RES (Sercombe et al., 2015). This is typically due to both their physical nature (large, spherical, and stiff objects are more quickly removed from the blood) and to the fact that they do not display proteins that mark the nanoparticle as the body's own cell (F. Chen et al., 2017; Vu et al., 2019; Zahednezhad et al., 2019).

Numerous strategies have been taken to endow nanoparticles with longer half-lives in blood. The decoration of the particles with polyethylene glycol (PEG) is perhaps the most successful "stealth" strategy. PEGylation, however, is falling out of favor due to the production and presence of anti-PEG antibodies (L. Yin et al., 2015), PEG tissue accumulation (Lane et al., 2017; Rippe et al., 2019), evidence of lack of PEG degradation, potentially creating vacuoles (Baumann et al., 2014; Ivens et al., 2015), and alteration of enzyme activity (Leuzzi et al., 2016). As such, alternatives to PEG such as heparosan are being developed (Lane et al., 2017; Rippe et al., 2019).

Decoration of particles with membranes derived from living cells is a powerful strategy to shield nanoparticles. This "semi-synthetic" approach, pioneered by Hu and colleagues, has proven highly versatile (C-M. J. Hu et al., 2011). All manner of cell membranes and cell membrane proteins have been used to coat nanoparticles and SCs (H. Cao et al., 2016; Corbo et al., 2017; Gao et al., 2015; C-M. J. Hu et al., 2013; Liang et al., 2018; L. Luo et al., 2017; Pitchaimani et al., 2018; J. Tang et al., 2017). This effectively shields the SCs from the RES and endows them with some of the signaling properties of the cells from which their borrowed membranes derive. As mentioned above, this strategy also enables targeting.

4 | CHALLENGES FACING SYNTHETIC CELL THERAPEUTICS

The field of synthetic cell engineering is relatively new, and many challenges still remain to be solved or even identified. These challenges include need for molecular tools, integration of disparate technologies, difficult manufacturing, and regulatory frameworks that disfavor complex drug formulations (Figure 3).

To coordinate release of therapeutic agents at the right location (e.g., at a tumor), more robust sense and respond mechanisms are needed. Currently, there is a relative lack of sensors that activate SCs in response to specific molecules, such as membrane proteins overexpressed on cancer cells. Such tools are now readily available in living cell therapies, such as CAR-T cells. Transferring natural membrane transduction systems to synthetic membranes is difficult due to their size, complexity, and requirements for post-translational modification and membrane insertion machinery. While bacterial transduction systems are smaller and relatively more robust proteins, they are likely immunogenic and cannot recognize eukaryotic membrane proteins. To enable reliable sensing of eukaryotic molecular markers of disease, a concerted effort is needed to engineer membrane transduction systems that function specifically in SCs.

A similar problem is the limited repertoire of trans-membrane channels available in synthetic cell systems. Living cells tightly control the flow of molecules in and out of the cell through channel proteins or membrane budding mechanisms. SCs, however, currently lack most of these systems. This is reflected in the prolific use of α -hemolysin, a simple and robust bacterial toxin that enables passive transport of small molecules. Only a few active transporters have been demonstrated in synthetic cells, including proteins as complex as ATP synthase. If more reliable membrane transporters could be identified and engineered to spontaneously insert into the membrane in the desired orientation, it would greatly broaden the sensing and delivery repertoire of SCs.

An issue for the entire field of synthetic cell engineering, including all therapeutic applications of this technology, is the integration of subsystems into one robust entity. As described in earlier sections of this review, many SC subsystems have been developed to demonstrate specific functionalities. Because each subsystem is engineered ad hoc, it is often difficult to reconcile their diverse chemistries and structures. To address this, several approaches can be taken. First, engineers in the field could standardize the chemical and structural framework in which they develop SCs. To encourage this, funding agencies could require adherence to these frameworks when it is sensible. Second, subsystems could be engineered with integration in mind by reporting subsystem performance across a variety of contexts. Last, computational models rooted in empirical data could be developed to guide the integration, much like what was done to guide the integration of synthetic genetic circuits (Nielsen et al., 2016).




FIGURE 3 Barriers to synthetic cell (SC) use in nanomedicine. Most fundamentally, new innovations and solutions are needed to endow SCs with modular functions that can perform reliably in physiological conditions. Next, production and cost barriers need to be addressed. Finally, therapeutic SCs will encounter regulatory hurdles that may require adapting current frameworks

To use synthetic cells as human therapeutics, other issues will need to be solved as well, like the toxicity of cell-free IVTT systems. While defined systems such as PURE contain mostly purified proteins, cell-derived fractions of ribosomes still contain some amount of endotoxins (i.e., lipopolysaccharides), which are highly pyrogenic. So far, only direct tumor injection was demonstrated as a method for localizing synthetic cells into a solid tumor in mice (Krinsky et al., 2018), and there is a relative lack of available data on half-lives and dose-dependent toxicity of synthetic cell formulations in animals.

As therapeutic applications of synthetic cells progress through foundational research and commercial R&D pipelines, the field will need to face technical challenges related to scaling up production of those novel therapeutics. Among those challenges, two areas present the most well-defined focus points: the compartment and the chemicals inside it.

Scaling up manufacturing of lipid vesicles to create membrane encapsulating synthetic cells will require progress in current microfluidic technology, or perhaps development of entirely new class of liposome formation technologies. Synthetic cells are typically larger than liposome drug delivery vehicles (single microns vs. tens of nanometers in diameter), and enzymes encapsulated inside synthetic cells cannot be encapsulated via remote loading used for some liposomal drugs. This creates a need for a whole new class of reliable, reproducible and scalable encapsulation techniques.

Similarly, producing large amounts of proteins and small molecules needed to provide therapeutic quantities of synthetic cells might require adjustment in supply chains. Production of cell-free protein expression systems is already scalable to 100-liter reaction volumes (Zawada et al., 2011), but availability of certain high value reagents remains a limiting step. We as a field anxiously await the invention of “PURE that makes PURE”—a cell-free IVTT reaction that can make every one of its own functional components and need little more than raw material as feedstock—as an idealized solution to the scaling problem.

Once synthetic cell technologies pass into animal testing, the need to fulfill FDA approval requirements will become critical. Currently, there are few guidelines for developing therapies as molecularly complex as synthetic cells. FDA approval is granted either for drugs with precisely controlled chemical composition, or for natural cell therapeutics. Synthetic cells, being made from synthetic components but not being descended from known living cells, may require a new framework by which such systems are evaluated. Uniformity of the formulation will remain critical, putting pressure on the above mentioned supply chain and scalability of membrane formulations. The FDA is already aware of the needs that might arise with progress of novel therapies using untested chassis, facilitating development of new oversight rules through the FDA Emerging Technologies Program. (Center for Drug Evaluation and Research, 2019) It will be critical that the synthetic cell community works closely with regulatory agencies to develop a supply pipeline and draft new frameworks for the testing and eventual deployment of those therapies for patient use.

5 | DISCUSSION AND OUTLOOK

Many have noted in recent years that as increased resources are devoted to development of drugs, ever fewer result in approved therapies. (Scannell et al., 2012) This phenomenon, known as Eroom's law (the reverse of Moore's law), highlights the need for new therapeutic modalities and approaches. Here we describe how synthetic cells offer a unique, engineerable platform for achieving a range of valuable therapeutic behaviors. These offer to augment existing means of drug delivery as well as tools for research and drug discovery pipelines. Though significant technical progress has been made in mimicking several advantageous features of living systems, the integration of these features remains a challenge, as do the development and manufacturing of such systems. Given recent progress, the vision of a synthetic cell that can identify and ameliorate disease in a programmable manner without adding risk of adverse effects looks less like a moonshot than an inevitable next step for medicine.

CONFLICT OF INTEREST

The authors have declared no conflicts of interest for this article.

AUTHOR CONTRIBUTIONS

Wakana Sato: Writing – original draft (equal); writing – review and editing (equal). **Tomasz Zajkowski:** Writing – original draft (equal); writing – review and editing (equal). **Katarzyna Adamala:** Conceptualization (equal); methodology (equal); project administration (equal); resources (equal); supervision (equal); validation (equal); visualization (equal); writing – original draft (equal); writing – review and editing (equal).

DATA AVAILABILITY STATEMENT

This review does not contain original research data.

ORCID

Wakana Sato  <https://orcid.org/0000-0002-5997-4438>

Tomasz Zajkowski  <https://orcid.org/0000-0001-9433-6071>

Katarzyna P. Adamala  <https://orcid.org/0000-0003-1066-7207>

RELATED WIREs ARTICLES

[Cell mimicry as a bottom-up strategy for hierarchical engineering of nature-inspired entities](#)

[Engineering spatiotemporal organization and dynamics in synthetic cells](#)

REFERENCES

- Abkarian, M., Loiseau, E., & Massiera, G. (2011). Continuous droplet interface crossing encapsulation (cDICE) for high throughput monodisperse vesicle design. *Soft Matter*, 7(10), 4610–4614. <https://doi.org/10.1039/C1SM05239J>
- Abraham, T., Mao, M., & Tan, C. (2018). Engineering approaches of smart, bio-inspired vesicles for biomedical applications. *Physical Biology*, 15(6), 061001. <https://doi.org/10.1088/1478-3975/aac7a2>
- Adamala, K. P., Martin-Alarcon, D. A., Guthrie-Honea, K. R., & Boyden, E. S. (2017). Engineering genetic circuit interactions within and between synthetic minimal cells. *Nature Chemistry*, 9(5), 431–439. <https://doi.org/10.1038/nchem.2644>
- Adams, D., Gonzalez-Duarte, A., O'Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., Lin, K. P., Vita, G., Attarian, S., Planté-Bordeneuve, V., Mezei, M. M., Campistol, J. M., Buades, J., Brannagan, T. H., Kim, B. J., ... Suhr, O. B. (2018). Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. *The New England Journal of Medicine*, 379(1), 11–21. <https://doi.org/10.1056/NEJMoa1716153>
- Adiga, R., Al-Adhami, M., Andar, A., Borhani, S., Brown, S., Burgenson, D., Cooper, M. A., Deldari, S., Frey, D. D., Ge, X., Guo, H., Gurramkonda, C., Jensen, P., Kostov, Y., LaCourse, W., Liu, Y., Moreira, A., Mupparapu, K., Peñalber-Johnstone, C., ... Zuber, A. (2018). Point-of-care production of therapeutic proteins of good-manufacturing-practice quality. *Nature Biomedical Engineering*, 2(9), 675–686. <https://doi.org/10.1038/s41551-018-0259-1>
- Adiga, R., Andar, A., Borhani, S., Burgenson, D., Deldari, S., Frey, D., Ge, X., Gopalakrishnan, M., Gurramkonda, C., Gutierrez, E., Jackson, I. L., Kostov, Y., Liu, Y., Moreira, A., Newman, D., Piegols, J., Punshon-Smith, B., Rao, G., Tolosa, L., ... Zodda, A. (2020). Manufacturing biological medicines on demand: Safety and efficacy of granulocyte colony-stimulating factor in a mouse model of total body irradiation. *Biotechnology Progress*, 36, e2970. <https://doi.org/10.1002/btpr.2970>
- Aghdam, A., Marjan, R. B., Mosafer, J., Baradaran, B., Hashemzadeh, M., Baghbazadeh, A., de la Guardia, M., & Mokhtarzadeh, A. (2019). Recent advances on thermosensitive and pH-sensitive liposomes employed in controlled release. *Journal of Controlled Release*, 315–(December), 1–22. <https://doi.org/10.1016/j.jconrel.2019.09.018>
- Aimon, S., Manzi, J., Schmidt, D., Larrosa, J. A. P., Bassereau, P., & Toombes, G. E. S. (2011). Functional reconstitution of a voltage-gated potassium channel in giant unilamellar vesicles. *PLoS One*, 6(10), e25529. <https://doi.org/10.1371/journal.pone.0025529>
- Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. *Advanced Drug Delivery Reviews*, 65(1), 36–48. <https://doi.org/10.1016/j.addr.2012.09.037>
- Altamura, E., Albanese, P., Marotta, R., Milano, F., Fiore, M., Trotta, M., Stano, P., & Mavelli, F. (2021). Chromatophores efficiently promote light-driven ATP synthesis and DNA transcription inside hybrid multicompartiment artificial cells. *Proceedings of the National Academy of Sciences*, 118(7), e2012170118. <https://doi.org/10.1073/pnas.2012170118>
- Amstad, E., Kohlbrecher, J., Müller, E., Schweizer, T., Textor, M., & Reimhult, E. (2011). Triggered release from liposomes through magnetic actuation of iron oxide nanoparticle containing membranes. *Nano Letters*, 11(4), 1664–1670. <https://doi.org/10.1021/nl2001499>
- Ando, M., Schikula, S., Sasaki, Y., & Akiyoshi, K. (2018). Proteoliposome engineering with cell-free membrane protein synthesis: Control of membrane protein sorting into liposomes by chaperoning systems. *Advancement of Science*, 5(10), 1800524. <https://doi.org/10.1002/adv.201800524>
- Angelova, M. I., & Dimitrov, D. S. (1986). Liposome electroformation. *Faraday Discussions of the Chemical Society*, 81(0), 303–311. <https://doi.org/10.1039/DC9868100303>
- Aufinger, L., & Simmel, F. C. (2018). Artificial gel-based organelles for spatial organization of cell-free gene expression reactions. *Angewandte Chemie*, 57(52), 17245–17248. <https://doi.org/10.1002/anie.201809374>
- Babincová, M., Cicmanec, P., Altanerová, V., Altaner, C., & Babinec, P. (2002). AC-magnetic field controlled drug release from magnetoliposomes: Design of a method for site-specific chemotherapy. *Bioelectrochemistry*, 55(1-2), 17–19. [https://doi.org/10.1016/s1567-5394\(01\)00171-2](https://doi.org/10.1016/s1567-5394(01)00171-2)
- Baimanov, D., Cai, R., & Chen, C. (2019). Understanding the chemical nature of nanoparticle-protein interactions. *Bioconjugate Chemistry*, 30(7), 1923–1937. <https://doi.org/10.1021/acs.bioconjchem.9b00348>
- Bartelt, S. M., Steinkühler, J., Dimova, R., & Wegner, S. V. (2018). Light-guided motility of a minimal synthetic cell. *Nano Letters*, 18, 7268–7274. <https://doi.org/10.1021/acs.nanolett.8b03469>

- Basic, D., Vacek, I., & Sun, A. M. (1996). Microencapsulation and transplantation of genetically engineered cells: A new approach to somatic gene therapy. *Artificial Cells, Blood Substitutes, and Biotechnology*, 24, 219–255. <https://doi.org/10.3109/10731199609117437>
- Baumann, A., Tuerck, D., Prabhu, S., Dickmann, L., & Sims, J. (2014). Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: Quo Vadis? *Drug Discovery Today*, 19, 1623–1631. <https://doi.org/10.1016/j.drudis.2014.06.002>
- Berardesca, E., Bertona, M., Altabas, K., Altabas, V., & Emanuele, E. (2012). Reduced ultraviolet-induced DNA damage and apoptosis in human skin with topical application of a photolyase-containing DNA repair enzyme cream: Clues to skin cancer prevention. *Molecular Medicine Reports*, 5(2), 570–574. <https://doi.org/10.3892/mmr.2011.673>
- Berhanu, S., Ueda, T., & Kuruma, Y. (2019). Artificial photosynthetic cell producing energy for protein synthesis. *Nature Communications*, 10(1), 1325. <https://doi.org/10.1038/s41467-019-09147-4>
- Biner, O., Fedor, J. G., Yin, Z., & Hirst, J. (2020). Bottom-up construction of a minimal system for cellular respiration and energy regeneration. *ACS Synthetic Biology*, 9(6), 1450–1459. <https://doi.org/10.1021/acssynbio.0c00110>
- Bloch, J., Bachoud-Lévi, A. C., Déglon, N., Lefaucheur, J. P., Winkel, L., Palfi, S., Nguyen, J. P., Bourdet, C., Gaura, V., Remy, P., Brugières, P., Boisse, M. F., Baudic, S., Cesaro, P., Hantraye, P., Aebischer, P., & Peschanski, M. (2004). Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: Results of a phase I study. *Human Gene Therapy*, 15(10), 968–975. <https://doi.org/10.1089/hum.2004.15.968>
- Boyer, C., & Zasadzinski, J. A. (2007). Multiple lipid compartments slow vesicle contents release in lipases and serum. *ACS Nano*, 1(3), 176–182. <https://doi.org/10.1021/nn7002025>
- Briuglia, M.-L., Rotella, C., McFarlane, A., & Lamprou, D. A. (2015). Influence of cholesterol on liposome stability and on in vitro drug release. *Drug Delivery and Translational Research*, 5(3), 231–242. <https://doi.org/10.1007/s13346-015-0220-8>
- Calafiore, R., Basta, G., Luca, G., Boselli, C., Bufalari, A., Bufalari, A., Cassarani, M. P., Giustozzi, G. M., & Brunetti, P. (1999). Transplantation of pancreatic islets contained in minimal volume microcapsules in diabetic high mammals. *Annals of the New York Academy of Sciences*, 875(June), 219–232. <https://doi.org/10.1111/j.1749-6632.1999.tb08506.x>
- Calhoun, K. A., & Swartz, J. R. (2005). Energizing cell-free protein synthesis with glucose metabolism. *Biotechnology and Bioengineering*, 90(5), 606–613. <https://doi.org/10.1002/bit.20449>
- Campbell, J., & Chang, T. M. S. (1978). Microencapsulated multi-enzyme systems as vehicles for the cyclic regeneration of free and immobilized coenzymes. In: Pye E.K., Weetall H.H. (eds) *Enzyme Engineering*. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-5163-5_42
- Cao, H., Dan, Z., He, X., Zhang, Z., Yu, H., Yin, Q., & Li, Y. (2016). Liposomes coated with isolated macrophage membrane can target lung metastasis of breast cancer. *ACS Nano*, 10(8), 7738–7748. <https://doi.org/10.1021/acsnano.6b03148>
- Cao, J., Li, C., Wei, X., Meiqing, T., Zhang, Y., Xu, F., & Yuhong, X. (2018). Selective targeting and eradication of LGR5 cancer stem cells using RSPO-conjugated doxorubicin liposomes. *Molecular Cancer Therapeutics*, 17(7), 1475–1485. <https://doi.org/10.1158/1535-7163.MCT-17-0694>
- Carter, K. A., Shao, S., Hoopes, M. I., Luo, D., Ahsan, B., Grigoryants, V. M., Song, W., Huang, H., Zhang, G., Pandey, R. K., Geng, J., Pfeifer, B. A., Scholes, C. P., Ortega, J., Karttunen, M., & Lovell, J. F. (2014). Porphyrin–phospholipid liposomes permeabilized by near-infrared light. *Nature Communications*, 5, 3546. <https://doi.org/10.1038/ncomms4546>
- Caschera, F., & Noireaux, V. (2015). A cost-effective polyphosphate-based metabolism fuels an all E. Coli cell-free expression system. *Metabolic Engineering*, 27, 29–37. <https://doi.org/10.1016/j.ymben.2014.10.007>
- Cattaneo, M. V., & Chang, T. M. (1991). The potential of a microencapsulated urease-zeolite oral sorbent for the removal of urea in uremia. *ASAIO Transactions/American Society for Artificial Internal Organs*, 37(2), 80–87. <https://www.ncbi.nlm.nih.gov/pubmed/1649615>
- Center for Drug Evaluation, and Research. (2019). Emerging Technology Program. October 10, 2019. <https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/emerging-technology-program>.
- Chang, H. N., Liu, B. Y., Qi, Y. K., Yang, Z., Chen, Y.-P., Pan, K. M., Li, W. W., Zhou, X. M., Ma, W. W., Fu, C. Y., Qi, Y. M., Liu, L., & Gao, Y. F. (2015). Blocking of the PD-1/PD-L1 interaction by a D-peptide antagonist for cancer immunotherapy. *Angewandte Chemie*, 54(40), 11760–11764. <https://doi.org/10.1002/anie.201506225>
- Chang, T. M. S. (1987). [7] recycling of NAD(P) by multienzyme systems immobilized by microencapsulation in artificial cells. *Immobilized Enzymes and Cells, Part C*, 136, 67–82. [https://doi.org/10.1016/s0076-6879\(87\)36009-4](https://doi.org/10.1016/s0076-6879(87)36009-4)
- Chang, T. M. S., & Poznansky, M. J. (1968). Semipermeable microcapsules containing catalase for enzyme replacement in acatalasaemic mice. *Nature*, 218, 243–245. <https://doi.org/10.1038/218243a0>
- Chang, T. M. S. (2005). Therapeutic applications of polymeric artificial cells. *Nature Reviews Drug Discovery*, 4, 221–235. <https://doi.org/10.1038/nrd1659>
- Chen, F., Wang, G., Griffin, J. I., Brenneman, B., Banda, N. K., Michael Holers, V., Backos, D. S., Wu, L., Moghimi, S. M., & Simberg, D. (2017). Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo. *Nature Nanotechnology*, 12(4), 387–393. <https://doi.org/10.1038/nnano.2016.269>
- Chen, Z., Silveira, G. D. Q., Ma, X., Xie, Y., Wu, Y. A., Barry, E., Tijana, R., Christopher Fry, H., Laible, P. D., & Rozhkova, E. A. (2019). Light-gated synthetic protocells for plasmon-enhanced chemiosmotic gradient generation and ATP synthesis. *Angewandte Chemie*, 131, 4950–4954. <https://doi.org/10.1002/ange.201813963>
- Chen, Z., Wang, J., Sun, W., Archibong, E., Kahkoska, A. R., Zhang, X., Lu, Y., Ligler, F. S., Buse, J. B., & Zhen, G. (2018). Synthetic beta cells for fusion-mediated dynamic insulin secretion. *Nature Chemical Biology*, 14(1), 86–93. <https://doi.org/10.1038/nchembio.2511>
- Chi, Y., Yin, X., Sun, K., Feng, S., Liu, J., Chen, D., Guo, C., & Zimei, W. (2017). Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models. *Journal of Controlled Release: Official Journal of the Controlled Release Society*, 261(September), 113–125. <https://doi.org/10.1016/j.jconrel.2017.06.027>

- Choi, H.-J., & Montemagno, C. D. (2005). Artificial organelle: ATP synthesis from cellular mimetic polymersomes. *Nano Letters*, 5, 2538–2542. <https://doi.org/10.1021/nl051896e>
- Cladera, J., Rigaud, J. L., Bottin, H., & Duñach, M. (1996). Functional reconstitution of photosystem I reaction center from cyanobacterium *Synechocystis* Sp PCC6803 into liposomes using a new reconstitution procedure. *Journal of Bioenergetics and Biomembranes*, 28(6), 503–515. <https://doi.org/10.1007/BF02110440>
- Corbo, C., Molinaro, R., Taraballi, F., Toledano Furman, N. E., Hartman, K. A., Sherman, M. B., De Rosa, E., Kirui, D. K., Salvatore, F., & Tasciotti, E. (2017). Unveiling the in vivo protein corona of circulating leukocyte-like carriers. *ACS Nano*, 11, 3262–3273. <https://doi.org/10.1021/acsnano.7b00376>
- Courbet, A., Amar, P., Fages, F., Renard, E., & Molina, F. (2018). Computer-aided biochemical programming of synthetic microreactors as diagnostic devices. *Molecular Systems Biology*, 14, e8441. <https://doi.org/10.15252/msb.20188441>
- Danhier, F. (2016). To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? *Journal of Controlled Release*, 244 (Pt A), 108–121. <https://doi.org/10.1016/j.jconrel.2016.11.015>
- de Ávila, E.-F., Berta, W. G., Karshalev, E., Zhang, L., & Wang, J. (2018). Cell-like micromotors. *Accounts of Chemical Research*, 51(9), 1901–1910. <https://doi.org/10.1021/acs.accounts.8b00202>
- De Leo, V., Milano, F., Mancini, E., Comparelli, R., Giotta, L., Nacci, A., Longobardi, F., Garbetta, A., Agostiano, A., & Catucci, L. (2018). Encapsulation of curcumin-loaded liposomes for colonic drug delivery in a pH-responsive polymer cluster using a pH-driven and organic solvent-free process. *Molecules*, 23, 739. <https://doi.org/10.3390/molecules23040739>
- de Vos, P., Hamel, A. F., & Tatarkiewicz, K. (2002). Considerations for successful transplantation of encapsulated pancreatic islets. *Diabetologia*, 45(2), 159–173. <https://doi.org/10.1007/s00125-001-0729-x>
- Deng, N.-N., Yelleswarapu, M., Zheng, L., & Huck, W. T. S. (2017). Microfluidic assembly of monodisperse vesosomes as artificial cell models. *Journal of the American Chemical Society*, 139(2), 587–590. <https://doi.org/10.1021/jacs.6b10977>
- Deng, Z., Yang, X., Pan, M., Li, F., Duan, W., Meng, L., Liu, X., Yan, F., & Zheng, H. (2016). Hyperthermia-triggered drug delivery from iRGD-modified temperature-sensitive liposomes enhances the anti-tumor efficacy using high intensity focused ultrasound. *Journal of Controlled Release*, 243(December), 333–341. <https://doi.org/10.1016/j.jconrel.2016.10.030>
- Deshpande, S., Caspi, Y., Meijering, A. E. C., & Dekker, C. (2016). Octanol-assisted liposome assembly on chip. *Nature Communications*, 7(January), 10447. <https://doi.org/10.1038/ncomms10447>
- Deshpande, S., Spoelstra, W. K., van Doorn, M., Kerssemakers, J., & Dekker, C. (2018). Mechanical division of cell-sized liposomes. *ACS Nano*, 12(3), 2560–2568. <https://doi.org/10.1021/acsnano.7b08411>
- Dhir, S., Salahub, S., Mathews, A. S., Kumaran, S. K., Montemagno, C. D., & Abraham, S. (2018). Light-induced ATP driven self-assembly of Actin and heavy-meromyosin in proteo-tubularsomes as a step toward artificial cells. *Chemical Communications*, 54(42), 5346–5349. <https://doi.org/10.1039/c8cc02691b>
- Ding, Y., Williams, N. H., & Hunter, C. A. (2019). A synthetic vesicle-to-vesicle communication system. *Journal of the American Chemical Society*, 141(44), 17847–17853. <https://doi.org/10.1021/jacs.9b09102>
- Dittrich, P. S., Heule, M., Renaud, P., & Manz, A. (2006). On-Chip extrusion of lipid vesicles and tubes through microsized apertures. *Lab on a Chip*, 6(4), 488–493. <https://doi.org/10.1039/b517670k>
- Doktorova, M., Heberle, F. A., Eicher, B., Standaert, R. F., Katsaras, J., London, E., Pabst, G., & Marquardt, D. (2018). Preparation of asymmetric phospholipid vesicles for use as cell membrane models. *Nature Protocols*, 13(9), 2086–2101. <https://doi.org/10.1038/s41596-018-0033-6>
- Dondapati, S. K., Wüstenhagen, D. A., Strauch, E., & Kubick, S. (2018). Cell-free production of pore forming toxins: Functional analysis of thermostable direct hemolysin from *Vibrio parahaemolyticus*. *Engineering in Life Sciences*, 18(2), 140–148. <https://doi.org/10.1002/elsc.201600259>
- Dudley, Q. M., Anderson, K. C., & Jewett, M. C. (2016). Cell-free mixing of *Escherichia coli* crude extracts to prototype and rationally engineer high-titer mevalonate synthesis. *ACS Synthetic Biology*, 5(12), 1578–1588. <https://doi.org/10.1021/acssynbio.6b00154>
- Dwidar, M., Seike, Y., Kobori, S., Whitaker, C., Matsuura, T., & Yokobayashi, Y. (2019). Programmable artificial cells using histamine-responsive synthetic riboswitch. *Journal of the American Chemical Society*, 141(28), 11103–11114. <https://doi.org/10.1021/jacs.9b03300>
- Elmore, D. E., & Dougherty, D. A. (2003). Investigating lipid composition effects on the mechanosensitive channel of large conductance (MscL) using molecular dynamics simulations. *Biophysical Journal*, 85(3), 1512–1524. [https://doi.org/10.1016/S0006-3495\(03\)74584-6](https://doi.org/10.1016/S0006-3495(03)74584-6)
- Enzian, P., Schell, C., Link, A., Malich, C., Pries, R., Wollenberg, B., & Rahmzadeh, R. (2020). Optically controlled drug release from light-sensitive liposomes with the new photosensitizer 5,10-DiOH. *Molecular Pharmaceutics*, 17(8), 2779–2788. <https://doi.org/10.1021/acs.molpharmaceut.9b01173>
- Fang, J., Islam, W., & Maeda, H. (2020). Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers. *Advanced Drug Delivery Reviews*, 157, 142–160. <https://doi.org/10.1016/j.addr.2020.06.005>
- Fang, R. H., Hu, C.-M. J., Luk, B. T., Gao, W., Copp, J. A., Tai, Y., O'Connor, D. E., & Zhang, L. (2014). Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. *Nano Letters*, 14(4), 2181–2188. <https://doi.org/10.1021/nl500618u>
- Fatouros, D. G., Lamprou, D. A., Urquhart, A. J., Yannopoulos, S. N., Vizirianakis, I. S., Zhang, S., & Koutsopoulos, S. (2014). Lipid-like self-assembling peptide nanovesicles for drug delivery. *ACS Applied Materials & Interfaces*, 6(11), 8184–8189. <https://doi.org/10.1021/am501673x>
- Feng, S., Wu, Z.-X., Zhao, Z., Liu, J., Sun, K., Guo, C., Wang, H., & Zimei, W. (2019). Engineering of bone- and CD44-dual-targeting redox-sensitive liposomes for the treatment of orthotopic osteosarcoma. *ACS Applied Materials & Interfaces*, 11(7), 7357–7368. <https://doi.org/10.1021/acсами.8b18820>

- Feng, X., Jia, Y., Cai, P., Fei, J., & Li, J. (2016). Coassembly of photosystem II and ATPase as artificial chloroplast for light-driven ATP synthesis. *ACS Nano*, *10*(1), 556–561. <https://doi.org/10.1021/acsnano.5b05579>
- Francia, V., Schiffelers, R. M., Cullis, P. R., & Witzigmann, D. (2020). The biomolecular corona of lipid nanoparticles for gene therapy. *Bioconjugate Chemistry*, *31*(9), 2046–2059. <https://doi.org/10.1021/acs.bioconjchem.0c00366>
- Fujii, S., Matsuura, T., Sunami, T., Nishikawa, T., Kazuta, Y., & Yomo, T. (2014). Liposome display for in vitro selection and evolution of membrane proteins. *Nature Protocols*, *9*(7), 1578–1591. <https://doi.org/10.1038/nprot.2014.107>
- Funakoshi, K., Suzuki, H., & Takeuchi, S. (2007). Formation of giant lipid vesiclelike compartments from a planar lipid membrane by a pulsed jet flow. *Journal of the American Chemical Society*, *129*(42), 12608–12609. <https://doi.org/10.1021/ja074029f>
- Gao, W., Cho, E., Liu, Y., & Yuan, L. (2019). Advances and challenges in cell-free incorporation of unnatural amino acids into proteins. *Frontiers in Pharmacology*, *10*(May), 611. <https://doi.org/10.3389/fphar.2019.00611>
- Gao, W., Fang, R. H., Thamphiwatana, S., Luk, B. T., Li, J., Angsantikul, P., Zhang, Q., Hu, C.-M. J., & Zhang, L. (2015). Modulating antibacterial immunity via bacterial membrane-coated nanoparticles. *Nano Letters*, *15*(2), 1403–1409. <https://doi.org/10.1021/nl504798g>
- Garamella, J., Majumder, S., Liu, A. P., & Noireaux, V. (2019). An adaptive synthetic cell based on mechanosensing, biosensing, and inducible gene circuits. *ACS Synthetic Biology*, *8*(8), 1913–1920. <https://doi.org/10.1021/acssynbio.9b00204>
- Geilich, B. M., Gelfat, I., Sridhar, S., van de Ven, A. L., & Webster, T. J. (2017). Superparamagnetic iron oxide-encapsulating polymersome nanocarriers for biofilm eradication. *Biomaterials*, *119*(March), 78–85. <https://doi.org/10.1016/j.biomaterials.2016.12.011>
- Gentile, K., Somasundar, A., Bhide, A., & Sen, A. (2020). Chemically powered synthetic ‘living’ systems. *Chem*, *6*, 2174–2185. <https://doi.org/10.1016/j.chempr.2020.08.010>
- Ghosh, S., Mohajerani, F., Son, S., Velegol, D., Butler, P. J., & Sen, A. (2019). Motility of enzyme-powered vesicles. *Nano Letters*, *19*(9), 6019–6026. <https://doi.org/10.1021/acs.nanolett.9b01830>
- Girard, P., Pécréaux, J., Lenoir, G., Falson, P., Rigaud, J.-L., & Bassereau, P. (2004). A new method for the reconstitution of membrane proteins into giant unilamellar vesicles. *Biophysical Journal*, *87*(1), 419–429. <https://doi.org/10.1529/biophysj.104.040360>
- Giulimondi, F., Digiacoio, L., Pozzi, D., Palchetti, S., Vulpis, E., Capriotti, A. L., Chiozzi, R. Z., Laganà, A., Amenitsch, H., Masuelli, L., Peruzzi, G., Mahmoudi, M., Screpanti, I., Zingoni, A., & Caracciolo, G. (2019). Interplay of protein corona and immune cells controls blood residency of liposomes. *Nature Communications*, *10*(1), 3686. <https://doi.org/10.1038/s41467-019-11642-7>
- Godoy-Gallardo, M., Labay, C., Trikalitis, V. D., Kempen, P. J., Larsen, J. B., Andresen, T. L., & Hosta-Rigau, L. (2017). Multicompartment artificial organelles conducting enzymatic cascade reactions inside cells. *ACS Applied Materials & Interfaces*, *9*(19), 15907–15921. <https://doi.org/10.1021/acsaami.6b16275>
- Gotanda, M., Kamiya, K., Osaki, T., Fujii, S., Misawa, N., Miki, N., & Takeuchi, S. (2018). Sequential generation of asymmetric lipid vesicles using a pulsed-jetting method in rotational wells. *Sensors and Actuators. B, Chemical*, *261*(May), 392–397. <https://doi.org/10.1016/j.snb.2018.01.149>
- Gray, B. P., Li, S., & Brown, K. C. (2013). From phage display to nanoparticle delivery: Functionalizing liposomes with multivalent peptides improves targeting to a cancer biomarker. *Bioconjugate Chemistry*, *24*(1), 85–96. <https://doi.org/10.1021/bc300498d>
- Grubbe, W. S., Razor, B. J., Krüger, A., Jewett, M. C., & Karim, A. S. (2020). Cell-free styrene biosynthesis at high titers. *Metabolic Engineering*, *61*(September), 89–95. <https://doi.org/10.1016/j.ymben.2020.05.009>
- Gu, K. F., & Chang, T. M. S. (1990). Conversion of ammonia or urea into essential amino acids, L-leucine, L-valine, and L-isoleucine using artificial cells containing an immobilized multienzyme system and dextran-NAD. *Journal of Molecular Catalysis*, *62*, 331–339. [https://doi.org/10.1016/0304-5102\(90\)85228-a](https://doi.org/10.1016/0304-5102(90)85228-a)
- Gulati, N. M., Stewart, P. L., & Steinmetz, N. F. (2018). Bioinspired shielding strategies for nanoparticle drug delivery applications. *Molecular Pharmaceutics*, *15*(8), 2900–2909. <https://doi.org/10.1021/acs.molpharmaceut.8b00292>
- Guo, H., Chen, W., Sun, X., Liu, Y.-N., Li, J., & Wang, J. (2015). Theranostic magnetoliposomes coated by carboxymethyl dextran with controlled release by low-frequency alternating magnetic field. *Carbohydrate Polymers*, *118*(March), 209–217. <https://doi.org/10.1016/j.carbpol.2014.10.076>
- Guo, P., Yang, J., Liu, D., Huang, L., Fell, G., Huang, J., Moses, M. A., & Auguste, D. T. (2019). Dual complementary liposomes inhibit triple-negative breast tumor progression and metastasis. *Science Advances*, *5*(3), eaav5010. <https://doi.org/10.1126/sciadv.aav5010>
- Haas, S., Hain, N., Raoufi, M., Handschuh-Wang, S., Wang, T., Jiang, X., & Schönherr, H. (2015). Enzyme degradable polymersomes from hyaluronic acid-block-poly(ϵ -caprolactone) copolymers for the detection of enzymes of pathogenic bacteria. *Biomacromolecules*, *16*(3), 832–841. <https://doi.org/10.1021/bm501729h>
- Haller, B., Göpfrich, K., Schröter, M., Janiesch, J.-W., Platzman, I., & Spatz, J. P. (2018). Charge-controlled microfluidic formation of lipid-based single- and multicompartment systems. *Lab on a Chip*, *18*(17), 2665–2674. <https://doi.org/10.1039/c8lc00582f>
- He, H., Lu, Y., Qi, J., Zhu, Q., Chen, Z., & Wei, W. (2019). Adapting liposomes for oral drug delivery. *Acta Pharmaceutica Sinica. B*, *9*(1), 36–48. <https://doi.org/10.1016/j.apsb.2018.06.005>
- Hortelão, A. C., García-Jimeno, S., Cano-Sarabia, M., Patiño, T., Maspoch, D., & Sanchez, S. (2020). LipoBots: Using liposomal vesicles as protective shell of urease-based nanomotors. *Advanced Functional Materials*, *30*, 2002767. <https://doi.org/10.1002/adfm.202002767>
- Hoshyar, N., Gray, S., Han, H., & Bao, G. (2016). The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. *Nanomedicine*, *11*(6), 673–692. <https://doi.org/10.2217/nnm.16.5>
- van den Hoven, J. M., Van Tomme, S. R., Metselaar, J. M., Nuijen, B., Beijnen, J. H., & Storm, G. (2011). Liposomal drug formulations in the treatment of rheumatoid arthritis. *Molecular Pharmaceutics*, *8*, 1002–1015. <https://doi.org/10.1021/mp2000742>
- Hu, C.-M. J., Zhang, L., Aryal, S., Cheung, C., Fang, R. H., & Zhang, L. (2011). Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. *Proceedings of the National Academy of Sciences*, *108*, 10980–10985. <https://doi.org/10.1073/pnas.1106634108>

- Hu, C.-M. J., Fang, R. H., Copp, J., Luk, B. T., & Zhang, L. (2013). A biomimetic Nanosponge that absorbs pore-forming toxins. *Nature Nanotechnology*, 8(5), 336–340. <https://doi.org/10.1038/nnano.2013.54>
- Hu, Q., Sun, W., Qian, C., Wang, C., Bomba, H. N., & Zhen, G. (2015). Anticancer platelet-mimicking nanovehicles. *Advanced Materials*, 27(44), 7043–7050. <https://doi.org/10.1002/adma.201503323>
- Hu, Y., & Qiu, L. (2019). Polymersomes: Preparation and characterization. In V. Weissig & T. Elbayoumi (Eds.), *Pharmaceutical nanotechnology: Basic protocols* (pp. 247–265). Springer New York. https://doi.org/10.1007/978-1-4939-9516-5_17
- Huang, X., Li, M., Green, D. C., Williams, D. S., Patil, A. J., & Mann, S. (2013). Interfacial assembly of protein-polymer Nano-conjugates into stimulus-responsive biomimetic protocells. *Nature Communications*, 4, 2239. <https://doi.org/10.1038/ncomms3239>
- Huang, X., Patil, A. J., Li, M., & Mann, S. (2014). Design and construction of higher-order structure and function in proteinosome-based protocells. *Journal of the American Chemical Society*, 136(25), 9225–9234. <https://doi.org/10.1021/ja504213m>
- Ito, Y., Nakagawa, S., Komagata, A., Ikeda-Saito, M., Shiro, Y., & Nakamura, H. (2009). Heme-dependent autophosphorylation of a heme sensor kinase, ChrS, from corynebacterium diphtheriae reconstituted in proteoliposomes. *FEBS Letters*, 583(13), 2244–2248. <https://doi.org/10.1016/j.febslet.2009.06.001>
- Ivens, I. A., Achanzar, W., Baumann, A., Brändli-Baiocco, A., Cavagnaro, J., Dempster, M., Depelchin, B. O., Rovira, A. R., Dill-Morton, L., Lane, J. H., Reipert, B.M., Salcedo, T., Schweighardt, B., Tsuruda, L. S., Turecek, P. L., & Sims, J. (2015). PEGylated biopharmaceuticals: Current experience and considerations for nonclinical development. *Toxicologic Pathology*, 43(7), 959–983. <https://doi.org/10.1177/0192623315591171>
- Iyer, R. K., Bowles, P. A., Kim, H., & Dulgar-Tulloch, A. (2018). Industrializing autologous adoptive immunotherapies: Manufacturing advances and challenges. *Frontiers of Medicine*, 5(May), 150. <https://doi.org/10.3389/fmed.2018.00150>
- Iyer, S., Karig, D. K., Elizabeth Norred, S., Simpson, M. L., & Doktycz, M. J. (2013). Multi-input regulation and logic with T7 promoters in cells and cell-free systems. *PLoS One*, 8(10), e78442. <https://doi.org/10.1371/journal.pone.0078442>
- Jahn, A., Vreeland, W. N., Gaitan, M., & Locascio, L. E. (2004). Controlled vesicle self-assembly in microfluidic channels with hydrodynamic focusing. *Journal of the American Chemical Society*, 126(9), 2674–2675. <https://doi.org/10.1021/ja0318030>
- Jaroentomeechai, T., Stark, J. C., Natarajan, A., Glasscock, C. J., Yates, L. E., Hsu, K. J., Mrksich, M., Jewett, M. C., & DeLisa, M. P. (2018). Single-pot glycoprotein biosynthesis using a cell-free transcription-translation system enriched with glycosylation machinery. *Nature Communications*, 9(1), 2686. <https://doi.org/10.1038/s41467-018-05110-x>
- Jewett, M. C., & Swartz, J. R. (2004). Mimicking the Escherichia Coli cytoplasmic environment activates long-lived and efficient cell-free protein synthesis. *Biotechnology and Bioengineering*, 86(1), 19–26. <https://doi.org/10.1002/bit.20026>
- Jones, R. B., Mueller, S., Kumari, S., Vrbanac, V., Genel, S., Tager, A. M., Allen, T. M., Walker, B. D., & Irvine, D. J. (2017). Antigen recognition-triggered drug delivery mediated by nanocapsule-functionalized cytotoxic T-cells. *Biomaterials*, 117(February), 44–53. <https://doi.org/10.1016/j.biomaterials.2016.11.048>
- Jose, A., Ninave, K. M., Karnam, S., & Venuganti, V. V. K. (2019). Temperature-sensitive liposomes for co-delivery of tamoxifen and imatinib for synergistic breast cancer treatment. *Journal of Liposome Research*, 29(2), 153–162. <https://doi.org/10.1080/08982104.2018.1502315>
- Joseph, A., Contini, C., Cecchin, D., Nyberg, S., Ruiz-Perez, L., Gaitzsch, J., Fullstone, G., Tian, X., Azizi, J., Preston, J., Volpe, G., & Battaglia, G. (2017). Chemotactic synthetic vesicles: Design and applications in blood-brain barrier crossing. *Science Advances*, 3(8), e1700362. <https://doi.org/10.1126/sciadv.1700362>
- Jung, K., Tjaden, B., & Altendorf, K. (1997). Purification, reconstitution, and characterization of KdpD, the turgor sensor of Escherichia Coli. *The Journal of Biological Chemistry*, 272(16), 10847–10852. <https://doi.org/10.1074/jbc.272.16.10847>
- Kamiya, K., Kawano, R., Osaki, T., Akiyoshi, K., & Takeuchi, S. (2016). Cell-sized asymmetric lipid vesicles facilitate the investigation of asymmetric membranes. *Nature Chemistry*, 8(9), 881–889. <https://doi.org/10.1038/nchem.2537>
- Kaneda, M., Nomura, S.-I. M., Ichinose, S., Kondo, S., Nakahama, K.-I., Akiyoshi, K., & Morita, I. (2009). Direct formation of proteoliposomes by in vitro synthesis and cellular cytosolic delivery with connexin-expressing liposomes. *Biomaterials*, 30(23–24), 3971–3977. <https://doi.org/10.1016/j.biomaterials.2009.04.006>
- Kim, M. W., Niidome, T., & Lee, R. (2019). Glycol chitosan-docosahexaenoic acid liposomes for drug delivery: Synergistic effect of doxorubicin-rapamycin in drug-resistant breast cancer. *Marine Drugs*, 17(10), 581. <https://doi.org/10.3390/md17100581>
- Kisovec, M., Rezelj, S., Knap, P., Cajnko, M. M., Caserman, S., Flašker, A., Žnidaršič, N., Repič, M., Mavri, J., Ruan, Y., Scheuring, S., Podobnik, M., & Anderluh, G. (2017). Engineering a pH responsive pore forming protein. *Scientific Reports*, 7, 67–82. <https://doi.org/10.1038/srep42231>
- Klermund, L., Poschenrieder, S. T., & Castiglione, K. (2017). Biocatalysis in polymersomes: improving multienzyme cascades with incompatible reaction steps by compartmentalization. *ACS Catalysis*, 7, 3900–3904. <https://doi.org/10.1021/acscatal.7b00776>
- Klyachko, N. L., Polak, R., Haney, M. J., Zhao, Y., Gomes Neto, R. J., Hill, M. C., Kabanov, A. V., Cohen, R. E., Rubner, M. F., & Batrakova, E. V. (2017). Macrophages with cellular backpacks for targeted drug delivery to the brain. *Biomaterials*, 140(September), 79–87. <https://doi.org/10.1016/j.biomaterials.2017.06.017>
- Kreir, M., Farre, C., Beckler, M., George, M., & Fertig, N. (2008). Rapid screening of membrane protein activity: Electrophysiological analysis of OmpF reconstituted in proteoliposomes. *Lab on a Chip*, 8(4), 587–595. <https://doi.org/10.1039/b713982a>
- Krinsky, N., Kaduri, M., Zinger, A., Shainsky-Roitman, J., Goldfeder, M., Benhar, I., HersHKovitz, D., & Schroeder, A. (2018). Synthetic cells synthesize therapeutic proteins inside tumors. *Advanced Healthcare Materials*, 7(9), e1701163. <https://doi.org/10.1002/adhm.201701163>
- Kuiper, S. M., Nallani, M., Vriezema, D. M., Cornelissen, J. J. L. M., van Hest, J. C. M., Nolte, R. J. M., & Rowan, A. E. (2008). Enzymes containing porous polymersomes as nano reaction vessels for cascade reactions. *Organic & Biomolecular Chemistry*, 6(23), 4315–4318. <https://doi.org/10.1039/b811196k>

- Kwon, Y.-C., & Jewett, M. C. (2015). High-throughput preparation methods of crude extract for robust cell-free protein synthesis. *Scientific Reports*, 5(March), 8663. <https://doi.org/10.1038/srep08663>
- Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012). Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress. *Journal of Controlled Release*, 161(2), 175–187. <https://doi.org/10.1016/j.jconrel.2011.09.063>
- Lane, R. S., Michael Haller, F., Chavarroche, A. A. E., Almond, A., & DeAngelis, P. L. (2017). Heparosan-coated liposomes for drug delivery. *Glycobiology*, 27(11), 1062–1074. <https://doi.org/10.1093/glycob/cwx070>
- Langton, M. J. (2020). Engineering of stimuli-responsive lipid-bilayer membranes using supramolecular systems. *Nature Reviews Chemistry*, 5, 46–61. <https://doi.org/10.1038/s41570-020-00233-6>
- Langton, M. J., Scriven, L. M., Williams, N. H., & Hunter, C. A. (2017). Triggered release from lipid bilayer vesicles by an artificial transmembrane signal transduction system. *Journal of the American Chemical Society*, 139(44), 15768–15773. <https://doi.org/10.1021/jacs.7b07747>
- Lavickova, B., & Maerkl, S. J. (2019). A simple, robust, and low-cost method to produce the pure cell-free system. *ACS Synthetic Biology*, 8(2), 455–462. <https://doi.org/10.1021/acssynbio.8b00427>
- Layek, B., Sadhukha, T., Panyam, J., & Prabha, S. (2018). Nano-engineered mesenchymal stem cells increase therapeutic efficacy of anticancer drug through true active tumor targeting. *Molecular Cancer Therapeutics*, 17(6), 1196–1206. <https://doi.org/10.1158/1535-7163.MCT-17-0682>
- Leduc, P. R., Wong, M. S., Ferreira, P. M., Groff, R. E., Haslinger, K., Koonce, M. P., Lee, W. Y., Love, J. C., McCammon, J. A., Monteiro-Riviere, N. A., Rotello, V. M., Rubloff, G. W., Westervelt, R., & Yoda, M. (2007). Towards an in vivo biologically inspired nanofactory. *Nature Nanotechnology*, 2(1), 3–7. <https://doi.org/10.1038/nnano.2006.180>
- Lentini, R., Martín, N. Y., Forlin, M., Belmonte, L., Fontana, J., Cornella, M., Martini, L., Tamburini, S., Bentley, W. E., Jousson, O., & Mansy, S. S. (2017). Two-way chemical communication between artificial and natural cells. *ACS Central Science*, 3(2), 117–123. <https://doi.org/10.1021/acscentsci.6b00330>
- Lentini, R., Santero, S. P., Chizzolini, F., Cecchi, D., Fontana, J., Marchioretto, M., Del Bianco, C., Terrell, J. L., Spencer, A. C., Martini, L., Forlin, M., Assfalg, M., Dalla, Serra, M., Bentley, W. E., & Mansy, S. S. (2014). Integrating artificial with natural cells to translate chemical messages that direct E. Coli behaviour. *Nature Communications*, 5, 4012. <https://doi.org/10.1038/ncomms5012>
- Leuzzi, V., Rossi, L., Gabucci, C., Nardecchia, F., & Magnani, M. (2016). Erythrocyte-mediated delivery of recombinant enzymes. *Journal of Inherited Metabolic Disease*, 39(4), 519–530. <https://doi.org/10.1007/s10545-016-9926-0>
- Liang, H., Huang, K., Su, T., Li, Z., Hu, S., Dinh, P. U., Wrona, E. A., Shao, C., Qiao, L., Vandergriff, A. C., Hensley, M. T., Cores, J., Allen, T., Zhang, H., Zeng, Q., Xing, J., Freytes, D. O., Shen, D., Yu, Z., & Cheng, K. (2018). Mesenchymal stem cell/red blood cell-inspired nanoparticle therapy in mice with carbon tetrachloride-induced acute liver failure. *ACS Nano*, 12(7), 6536–6544. <https://doi.org/10.1021/acsnano.8b00553>
- Lim, F., & Sun, A. (1980). Microencapsulated islets as bioartificial endocrine pancreas. *Science*, 210, 908–910. <https://doi.org/10.1126/science.6776628>
- Liu, F., Kozlovskaya, V., Medipelli, S., Xue, B., Ahmad, F., Saeed, M., Crokek, D., & Kharlampieva, E. (2015). Temperature-sensitive polymersomes for controlled delivery of anticancer drugs. *Chemistry of Materials*, 27, 7945–7956. <https://doi.org/10.1021/acs.chemmater.5b03048>
- Liu, H., Zhigang, T., Feng, F., Shi, H., Chen, K., & Ximing, X. (2015). Virosome, a hybrid vehicle for efficient and safe drug delivery and its emerging application in cancer treatment. *Acta Pharmaceutica*, 65(2), 105–116. <https://doi.org/10.1515/acph-2015-0019>
- Liu, S., Zhang, Y., Li, M., Xiong, L., Zhang, Z., Yang, X., He, X., Wang, K., Liu, J., & Mann, S. (2020). Enzyme-mediated nitric oxide production in vasoactive erythrocyte membrane-enclosed coacervate protocells. *Nature Chemistry*, 12(12), 1165–1173. <https://doi.org/10.1038/s41557-020-00585-y>
- Liu, X., Silverman, A. D., Alam, K. K., Iverson, E., Lucks, J. B., Jewett, M. C., & Raman, S. (2020). Design of a transcriptional biosensor for the portable, on-demand detection of cyanuric acid. *ACS Synthetic Biology*, 9(1), 84–94. <https://doi.org/10.1021/acssynbio.9b00348>
- Lizano, C., Sanz, S., Luque, J., & Pinilla, M. (1998). In vitro study of alcohol dehydrogenase and acetaldehyde dehydrogenase encapsulated into human erythrocytes by an electroporation procedure. *Biochimica et Biophysica Acta*, 1425(2), 328–336. [https://doi.org/10.1016/s0304-4165\(98\)00085-3](https://doi.org/10.1016/s0304-4165(98)00085-3)
- Lizano, C., Teresa Pérez, M., & Pinilla, M. (2001). Mouse erythrocytes as carriers for coencapsulated alcohol and aldehyde dehydrogenase obtained by electroporation. *Life Sciences*, 68, 2001–2016. [https://doi.org/10.1016/s0024-3205\(01\)00991-2](https://doi.org/10.1016/s0024-3205(01)00991-2)
- Lobatto, M. E., Calcagno, C., Millon, A., Senders, M. L., Fay, F., Robson, P. M., Ramachandran, S., Binderup, T., Paridaans, M. P. M., Sensarn, S., Rogalla, S., Gordon, R. E., Cardoso, L., Storm, G., Metselaar, J. M., Contag, C. H., Stroes, E. S. G., Fayad, Z. A., & Mulder, W. J. M. (2015). Atherosclerotic plaque targeting mechanism of long-circulating nanoparticles established by multimodal imaging. *ACS Nano*, 9(2), 1837–1847. <https://doi.org/10.1021/nn506750r>
- Löhr, M., Hoffmeyer, A., Kröger, J., Freund, M., Hain, J., Holle, A., Karle, P., Knöfel, W. T., Liebe, S., Müller, P., Nizze, H., Renner, M., Saller, R. M., Wagner, T., Hauenstein, K., Günzburg, W. H., & Salmons, B. (2001). Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. *The Lancet*, 357(9268), 1591–1592. [https://doi.org/10.1016/s0140-6736\(00\)04749-8](https://doi.org/10.1016/s0140-6736(00)04749-8)
- Louhivuori, M., Risselada, H. J., van der Giessen, E., & Marrink, S. J. (2010). Release of content through Mechano-sensitive gates in pressurized liposomes. *Proceedings of the National Academy of Sciences of the United States of America*, 107(46), 19856–19860. <https://doi.org/10.1073/pnas.1001316107>
- Lu, M., Zhao, X., Xing, H., Liu, H., Lang, L., Yang, T., Xun, Z., Wang, D., & Ding, P. (2019). Cell-free synthesis of connexin 43-integrated exosome-mimetic nanoparticles for siRNA delivery. *Acta Biomaterialia*, 96(September), 517–536. <https://doi.org/10.1016/j.actbio.2019.07.006>

- Luo, D., Carter, K. A., Razi, A., Geng, J., Shao, S., Giraldo, D., Sunar, U., Ortega, J., & Lovell, J. F. (2016). Doxorubicin encapsulated in stealth liposomes conferred with light-triggered drug release. *Biomaterials*, *75*(January), 193–202. <https://doi.org/10.1016/j.biomaterials.2015.10.027>
- Luo, L., Tang, J., Nishi, K., Yan, C., Dinh, P.-U., Cores, J., Kudo, T., Zhang, J., Li, T.-S., & Cheng, K. (2017). Fabrication of synthetic mesenchymal stem cells for the treatment of acute myocardial infarction in mice. *Circulation Research*, *120*(11), 1768–1775. <https://doi.org/10.1161/CIRCRESAHA.116.310374>
- Lvov, Y., Antipov, A. A., Mamedov, A., Möhwald, H., & Sukhorukov, G. B. (2001). Urease encapsulation in nanoorganized microshells. *Nano Letters*, *1*, 125–128. <https://doi.org/10.1021/nl0100015>
- Majumder, J., & Minko, T. (2020). Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery. *Expert Opinion on Drug Delivery*, *18*(October), 1–23. <https://doi.org/10.1080/17425247.2021.1828339>
- Martin, R. W., Des, Soye, B. J., Kwon, Y. C., Kay, J., Davis, R. G., Thomas, P. M., Majewska, N. I., Chen, C. X., Marcum, R. D., Weiss, M. G., Stoddart, A. E., Amiram, M., Ranji, Charna, A. K., Patel, J. R., Isaacs, F. J., Kelleher, N. L., Hong, S. H., & Jewett, M. C. (2018). Cell-free protein synthesis from genomically recoded bacteria enables multisite incorporation of noncanonical amino acids. *Nature Communications*, *9*(1), 1203. <https://doi.org/10.1038/s41467-018-03469-5>
- Maruyama, K., Yuda, T., Okamoto, A., Kojima, S., Suginaka, A., & Iwatsuru, M. (1992). Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphiphathic poly(ethylene glycol). *Biochimica et Biophysica Acta*, *1128*(1), 44–49. [https://doi.org/10.1016/0005-2760\(92\)90255-t](https://doi.org/10.1016/0005-2760(92)90255-t)
- de Matos, M. B. C., Miranda, B. S., Nuari, Y. R., Storm, G., Lenewit, G., Schifflers, R. M., & Kok, R. J. (2019). Liposomes with asymmetric bilayers produced from inverse emulsions for nucleic acid delivery. *Journal of Drug Targeting*, *27*(5–6), 681–689. <https://doi.org/10.1080/1061186X.2019.1579819>
- Matosevic, S., & Paegel, B. M. (2011). Stepwise synthesis of giant unilamellar vesicles on a microfluidic assembly line. *Journal of the American Chemical Society*, *133*(9), 2798–2800. <https://doi.org/10.1021/ja109137s>
- Meeuwissen, S. A., Rioz-Martínez, A., de Gonzalo, G., Fraaije, M. W., Gotor, V., & van Hest, J. C. M. (2011). Cofactor regeneration in polymersome nanoreactors: Enzymatically catalysed Baeyer–Villiger reactions. *Journal of Materials Chemistry*, *21*, 18923. <https://doi.org/10.1039/c1jm12407b>
- Miele, Y., Medveczky, Z., Holló, G., Tegze, B., Derényi, I., Hórvölgyi, Z., Altamura, E., Lagzi, I., & Rossi, F. (2020). Self-division of giant vesicles driven by an internal enzymatic reaction. *Chemical Science*, *11*, 3228–3235. <https://doi.org/10.1039/c9sc05195c>
- Miranda, D., & Lovell, J. F. (2016). Mechanisms of light-induced liposome permeabilization. *Bioengineering & Translational Medicine*, *1*, 267–276. <https://doi.org/10.1002/btm2.10032>
- Mirhadi, E., Mashreghi, M., Maleki, M. F., Alavizadeh, S. H., Arabi, L., Badiie, A., & Jaafari, M. R. (2020). Redox-sensitive nanoscale drug delivery systems for cancer treatment. *International Journal of Pharmaceutics*, *589*(September), 119882. <https://doi.org/10.1016/j.ijpharm.2020.119882>
- Morsut, L., Roybal, K. T., Xiong, X., Gordley, R. M., Coyle, S. M., Thomson, M., & Lim, W. A. (2016). Engineering customized cell sensing and response behaviors using synthetic notch receptors. *Cell*, *164*, 780–791. <https://doi.org/10.1016/j.cell.2016.01.012>
- Natfji, A. A., Ravishankar, D., Osborn, H. M. I., & Greco, F. (2017). Parameters affecting the enhanced permeability and retention effect: The need for patient selection. *Journal of Pharmaceutical Sciences*, *106*(11), 3179–3187. <https://doi.org/10.1016/j.xphs.2017.06.019>
- Nawroth, J. C., Lee, H., Feinberg, A. W., Ripplinger, C. M., McCain, M. L., Grosberg, A., Dabiri, J. O., & Parker, K. K. (2012). A tissue-engineered jellyfish with biomimetic propulsion. *Nature Biotechnology*, *30*(8), 792–797. <https://doi.org/10.1038/nbt.2269>
- Naziris, N., Pippa, N., Meristoudi, A., Pispas, S., & Demetzos, C. (2017). Design and development of pH-responsive HSPC:CH-PAA chimeric liposomes. *Journal of Liposome Research*, *27*(2), 108–117. <https://doi.org/10.3109/08982104.2016.1166512>
- Needham, D., Anyambhatla, G., Kong, G., & Dewhirst, M. W. (2000). A new temperature-sensitive liposome for use with mild hyperthermia: Characterization and testing in a human tumor xenograft model. *Cancer Research*, *60*(5), 1197–1201 <https://cancerres.aacrjournals.org/content/60/5/1197.abstract>
- Niederholtmeyer, H., Chagga, C., & Devaraj, N. K. (2018). Communication and quorum sensing in non-living mimics of eukaryotic cells. *Nature Communications*, *9*(1), 5027. <https://doi.org/10.1038/s41467-018-07473-7>
- Nielsen, A. A. K., Der, B. S., Shin, J., Vaidyanathan, P., Paralanov, V., Strychalski, E. A., Ross, D., Densmore, D., & Voigt, C. A. (2016). Genetic circuit design automation. *Science*, *352*(6281), aac7341. <https://doi.org/10.1126/science.aac7341>
- Niesman, M. R., Johnson, K. A., & Penn, J. S. (1997). Therapeutic effect of liposomal superoxide dismutase in an animal model of retinopathy of prematurity. *Neurochemical Research*, *22*(5), 597–605. <https://doi.org/10.1023/a:1022474120512>
- Nikkhoi, K., Shahryar, F. R., Ahmadvand, D., & Moghimi, S. M. (2018). Multivalent targeting and killing of HER2 overexpressing breast carcinoma cells with methotrexate-encapsulated tetra-specific non-overlapping variable domain heavy chain anti-HER2 antibody-PEG-liposomes: In vitro proof-of-concept. *European Journal of Pharmaceutical Sciences*, *122*(September), 42–50. <https://doi.org/10.1016/j.ejps.2018.06.019>
- Noireaux, V., & Libchaber, A. (2004). A vesicle bioreactor as a step toward an artificial cell assembly. *Proceedings of the National Academy of Sciences of the United States of America*, *101*(51), 17669–17674. <https://doi.org/10.1073/pnas.0408236101>
- Ohta, N., Kato, Y., Watanabe, H., Mori, H., & Matsuura, T. (2016). In vitro membrane protein synthesis inside sec translocon-reconstituted cell-sized liposomes. *Scientific Reports*, *6*(November), 36466. <https://doi.org/10.1038/srep36466>
- Oliveira, H., Pérez-Andrés, E., Thevenot, J., Sandre, O., Berra, E., & Lecommandoux, S. (2013). Magnetic field triggered drug release from polymersomes for cancer therapeutics. *Journal of Controlled Release: Official Journal of the Controlled Release Society*, *169*(3), 165–170. <https://doi.org/10.1016/j.jconrel.2013.01.013>

- Oliveira, S., Schifflers, R. M., van der Veeke, J., van der Meel, R., Vongprommek, R., van Bergen En Henegouwen, P. M. P., Storm, G., & Roovers, R. C. (2010). Downregulation of EGFR by a novel multivalent nanobody-liposome platform. *Journal of Controlled Release*, *145*(2), 165–175. <https://doi.org/10.1016/j.jconrel.2010.03.020>
- Orth, J. H. C., Schorch, B., Boundy, S., Ffrench-Constant, R., Kubick, S., & Aktories, K. (2011). Cell-free synthesis and characterization of a novel cytotoxic pierisin-like protein from the cabbage butterfly *Pieris rapae*. *Toxicon*, *57*(2), 199–207. <https://doi.org/10.1016/j.toxicon.2010.11.011>
- Ota, S., Yoshizawa, S., & Takeuchi, S. (2009). Microfluidic formation of monodisperse, cell-sized, and unilamellar vesicles. *Angewandte Chemie*, *48*(35), 6533–6537. <https://doi.org/10.1002/anie.200902182>
- Pan, J., Yancheng, D., Qiu, H., Upton, L. R., Li, F., & Choi, J. H. (2019). Mimicking chemotactic cell migration with DNA programmable synthetic vesicles. *Nano Letters*, *19*(12), 9138–9144. <https://doi.org/10.1021/acs.nanolett.9b04428>
- Pardee, K., Slomovic, S., Nguyen, P. Q., Lee, J. W., Donghia, N., Burrill, D., Ferrante, T., McSorley, F. R., Furuta, Y., Vernet, A., Lewandowski, M., Boddy, C. N., Joshi, N. S., & Collins, J. J. (2016). Portable, on-demand biomolecular manufacturing. *Cell*, *167*(1), 248–259. <https://doi.org/10.1016/j.cell.2016.09.013>
- Pattipeiluhu, R., Crielaard, S., Klein-Schiphorst, I., Florea, B. I., Kros, A., & Campbell, F. (2020). Unbiased identification of the liposome protein corona using photoaffinity-based chemoproteomics. *ACS Central Science*, *6*(4), 535–545. <https://doi.org/10.1021/acscentsci.9b01222>
- Pautot, S., Frisken, B. J., & Weitz, D. A. (2003). Production of unilamellar vesicles using an inverted emulsion. *Langmuir: The ACS Journal of Surfaces and Colloids*, *19*(7), 2870–2879. <https://doi.org/10.1021/la026100v>
- Peng, F., Yingfeng, T., van Hest, J. C. M., & Wilson, D. A. (2015). Self-guided supramolecular cargo-loaded nanomotors with chemotactic behavior towards cells. *Angewandte Chemie*, *54*(40), 11662–11665. <https://doi.org/10.1002/anie.201504186>
- Peters, R. J. R. W., Nijemeisland, M., & van Hest, J. C. M. (2015). Reversibly triggered protein-ligand assemblies in giant vesicles. *Angewandte Chemie*, *54*(33), 9614–9617. <https://doi.org/10.1002/anie.201502920>
- Peyret, A., Ibarboure, E., Tron, A., Beauté, L., Rust, R., Sandre, O., McClenaghan, N. D., & Lecommandoux, S. (2017). Polymersome popping by light-induced osmotic shock under temporal, spatial, and spectral control. *Angewandte Chemie International Edition*, *56*, 1566–1570. <https://doi.org/10.1002/anie.201609231>
- Pflüger, T., Hernández, C. F., Lewe, P., Frank, F., Mertens, H., Svergun, D., Baumstark, M. W., Lunin, V. Y., Jetten, M. S. M., & Andrade, S. L. A. (2018). Signaling ammonium across membranes through an ammonium sensor histidine kinase. *Nature Communications*, *9*(1), 164. <https://doi.org/10.1038/s41467-017-02637-3>
- Photos, P. J., Bacakova, L., Discher, B., Bates, F. S., & Discher, D. E. (2003). Polymer vesicles in Vivo: Correlations with PEG molecular weight. *Journal of Controlled Release: Official Journal of the Controlled Release Society*, *90*(3), 323–334. [https://doi.org/10.1016/s0168-3659\(03\)00201-3](https://doi.org/10.1016/s0168-3659(03)00201-3)
- Pitchaimani, A., Nguyen, T. D. T., & Aryal, S. (2018). Natural killer cell membrane infused biomimetic liposomes for targeted tumor therapy. *Biomaterials*, *160*, 124–137. <https://doi.org/10.1016/j.biomaterials.2018.01.018>
- Pontani, L.-L., van der Gucht, J., Salbreux, G., Heuvingh, J., Joanny, J.-F., & Sykes, C. (2009). Reconstitution of an Actin cortex inside a liposome. *Biophysical Journal*, *96*(1), 192–198. <https://doi.org/10.1016/j.bpj.2008.09.029>
- Pös, O., Biró, O., Szemes, T., & Nagy, B. (2018). Circulating cell-free nucleic acids: Characteristics and applications. *European Journal of Human Genetics: EJHG*, *26*(7), 937–945. <https://doi.org/10.1038/s41431-018-0132-4>
- Pratsinis, A., Zuercher, S., Forster, V., Fischer, E. J., Luciani, P., & Leroux, J.-C. (2017). Liposome-supported enzymatic peritoneal dialysis. *Biomaterials*, *145*(November), 128–137. <https://doi.org/10.1016/j.biomaterials.2017.08.016>
- Qu, B., Li, X., Guan, M., Li, X., Hai, L., & Yong, W. (2014). Design, synthesis and biological evaluation of multivalent glucosides with high affinity as ligands for brain targeting liposomes. *European Journal of Medicinal Chemistry*, *72*(January), 110–118. <https://doi.org/10.1016/j.ejmech.2013.10.007>
- Rao, D. R., Chawan, C. B., & Veeramachaneni, R. (1994). Liposomal encapsulation of β -Galactosidase: Comparison of two methods of encapsulation and in vitro lactose digestibility. *Journal of Food Biochemistry*, *18*, 239–251. <https://doi.org/10.1111/j.1745-4514.1994.tb00500.x>
- Ravikumar, S., Baylon, M. G., Park, S. J., & Choi, J.-I. (2017). Engineered microbial biosensors based on bacterial two-component systems as synthetic biotechnology platforms in bioremediation and biorefinery. *Microbial Cell Factories*, *16*(1), 62. <https://doi.org/10.1186/s12934-017-0675-z>
- Riedl, C. R., Sternig, P., Gallé, G., Langmann, F., Vcelar, B., Vorauer, K., Wagner, A., Katinger, H., & Pflüger, H. (2005). Liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease: A randomized placebo-controlled double-blind prospective clinical study. *European Urology*, *48*, 656–661. <https://doi.org/10.1016/j.eururo.2005.04.011>
- Rippe, M., Stefanello, T. F., Kaplum, V., Britta, E. A., Garcia, F. P., Poirot, R., Companhoni, M. V. P., Nakamura, C. V., Szarpak-Jankowska, A., & Auzély-Velty, R. (2019). Heparosan as a potential alternative to hyaluronic acid for the design of biopolymer-based nanovectors for anticancer therapy. *Biomaterials Science*, *7*(7), 2850–2860. <https://doi.org/10.1039/C9BM00443B>
- Rwei, A. Y., Paris, J. L., Wang, B., Wang, W., Axon, C. D., Vallet-Regí, M., Langer, R., & Kohane, D. S. (2017). Ultrasound-triggered local anaesthesia. *Nature Biomedical Engineering*, *1*(August), 644–653. <https://doi.org/10.1038/s41551-017-0117-6>
- Sabino, C. P., Deana, A. M., Yoshimura, T. M., da Silva, D. F. T., França, C. M., Hamblin, M. R., & Ribeiro, M. S. (2016). The optical properties of mouse skin in the visible and near infrared spectral regions. *Journal of Photochemistry and Photobiology B: Biology*, *160*, 72–78. <https://doi.org/10.1016/j.jphotobiol.2016.03.047>
- Salehi, A. S. M., Shakalli Tang, M. J., Smith, M. T., Hunt, J. M., Law, R. A., Wood, D. W., & Bundy, B. C. (2017). Cell-free protein synthesis approach to biosensing hTR β -specific endocrine disruptors. *Analytical Chemistry*, *89*(6), 3395–3401. <https://doi.org/10.1021/acs.analchem.6b04034>

- Salehi, A. S. M., Smith, M. T., Bennett, A. M., Williams, J. B., Pitt, W. G., & Bundy, B. C. (2016). Cell-free protein synthesis of a cytotoxic cancer therapeutic: Onconase production and a just-add-water cell-free system. *Biotechnology Journal*, *11*(2), 274–281. <https://doi.org/10.1002/biot.201500237>
- Sanowar, S., & Le Moual, H. (2005). Functional reconstitution of the salmonella typhimurium PhoQ histidine kinase sensor in proteoliposomes. *Biochemical Journal*, *390* (Pt 3), 769–776. <https://doi.org/10.1042/BJ20050060>
- Sarkar, S., Alam, M. A., Shaw, J., & Dasgupta, A. K. (2013). Drug delivery using platelet cancer cell interaction. *Pharmaceutical Research*, *30*(11), 2785–2794. <https://doi.org/10.1007/s11095-013-1097-1>
- Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012). Diagnosing the decline in pharmaceutical R&D efficiency. *Nature Reviews. Drug Discovery*, *11*(3), 191–200. <https://doi.org/10.1038/nrd3681>
- Schroeder, A., Goldberg, M. S., Kastrup, C., Wang, Y., Jiang, S., Joseph, B. J., Levins, C. G., Kannan, S. T., Langer, R., & Anderson, D. G. (2012). Remotely activated protein-producing nanoparticles. *Nano Letters*, *12*(6), 2685–2689. <https://doi.org/10.1021/nl2036047>
- Schuetz, C. G., Hatsuzawa, K., Margittai, M., Stein, A., Riedel, D., Küster, P., König, M., Seidel, C., & Jahn, R. (2004). Determinants of liposome fusion mediated by synaptic SNARE proteins. *Proceedings of the National Academy of Sciences of the United States of America*, *101*(9), 2858–2863. <https://doi.org/10.1073/pnas.0400044101>
- Schwarz-Schilling, M., Aufinger, L., Mückl, A., & Simmel, F. C. (2016). Chemical communication between bacteria and cell-free gene expression systems within linear chains of emulsion droplets. *Integrative Biology: Quantitative Biosciences from Nano to Macro*, *8*(4), 564–570. <https://doi.org/10.1039/c5ib00301f>
- Sercombe, L., Veerati, T., Moheimani, F., Wu, S. Y., Sood, A. K., & Hua, S. (2015). Advances and challenges of liposome assisted drug delivery. *Frontiers in Pharmacology*, *6*(December), 286. <https://doi.org/10.3389/fphar.2015.00286>
- Shah, S., Dhawan, V., Holm, R., Nagarsenker, M. S., & Perrie, Y. (2020). Liposomes: Advancements and innovation in the manufacturing process. *Advanced Drug Delivery Reviews*, *154–155*(July), 102–122. <https://doi.org/10.1016/j.addr.2020.07.002>
- Shazeb, M. S., Feula, G., & Bogdanov, A. (2014). Liposome-encapsulated superoxide dismutase mimetic: Theranostic potential of an MR detectable and neuroprotective agent. *Contrast Media & Molecular Imaging*, *9*, 221–228. <https://doi.org/10.1002/cmim.1559>
- Shekhar, H., Bader, K. B., Huang, S., Peng, T., Huang, S., McPherson, D. D., & Holland, C. K. (2017). In vitro thrombolytic efficacy of echogenic liposomes loaded with tissue plasminogen activator and octafluoropropane gas. *Physics in Medicine and Biology*, *62*, 517–538. <https://doi.org/10.1088/1361-6560/62/2/517>
- Shi, C., Li, M., Zhang, Z., Yao, Q., Shao, K., Xu, F., Xu, N., Li, H., Fan, J., Sun, W., du, J., Long, S., Wang, J., & Peng, X. (2020). Catalase-based liposomal for reversing immunosuppressive tumor microenvironment and enhanced cancer chemo-photodynamic therapy. *Biomaterials*, *233*(March), 119755. <https://doi.org/10.1016/j.biomaterials.2020.119755>
- Shimizu, Y., Inoue, A., Tomari, Y., Suzuki, T., Yokogawa, T., Nishikawa, K., & Ueda, T. (2001). Cell-free translation reconstituted with purified components. *Nature Biotechnology*, *19*(8), 751–755. <https://doi.org/10.1038/90802>
- Shimizu, Y., & Ueda, T. (2010). PURE technology. *Methods in Molecular Biology*, *607*, 11–21. https://doi.org/10.1007/978-1-60327-331-2_2
- Shis, D. L., Hussain, F., Meinhardt, S., Swint-Kruse, L., & Bennett, M. R. (2014). Modular, multi-input transcriptional logic gating with orthogonal LacI/GalR family chimeras. *ACS Synthetic Biology*, *3*(9), 645–651. <https://doi.org/10.1021/sb500262f>
- Shum, H. C., Lee, D., Yoon, I., Kodger, T., & Weitz, D. A. (2008). Double emulsion templated monodisperse phospholipid vesicles. *Langmuir: The ACS Journal of Surfaces and Colloids*, *24*(15), 7651–7653. <https://doi.org/10.1021/la801833a>
- Silverman, A. D., Karim, A. S., & Jewett, M. C. (2020). Cell-free gene expression: An expanded repertoire of applications. *Nature Reviews. Genetics*, *21*(3), 151–170. <https://doi.org/10.1038/s41576-019-0186-3>
- Siton-Mendelson, O., & Bernheim-Groswasser, A. (2016). Toward the reconstitution of synthetic cell motility. *Cell Adhesion & Migration*, *10*(5), 461–474. <https://doi.org/10.1080/19336918.2016.1170260>
- Soga, N., Ota, A., Nakajima, K., Watanabe, R., Ueno, H., & Noji, H. (2020). Monodisperse liposomes with femtoliter volume enable quantitative digital bioassays of membrane transporters and cell-free gene expression. *ACS Nano*, *14*(9), 11700–11711. <https://doi.org/10.1021/acsnano.0c04354>
- Somasundar, A., Ghosh, S., Mohajerani, F., Massenburg, L. N., Yang, T., Cremer, P. S., Velegol, D., & Sen, A. (2019). Positive and negative chemotaxis of enzyme-coated liposome motors. *Nature Nanotechnology*, *14*(12), 1129–1134. <https://doi.org/10.1038/s41565-019-0578-8>
- Soon-Shiong, P., Heintz, R. E., Merideth, N., Yao, Q. X., Yao, Z., Zheng, T., Murphy, M., Moloney, M. K., Schmehl, M., Harris, M., Mendez, R., Mendez, R., & Sandford, P. A. (1994). Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation. *The Lancet*, *343*, 950–951. [https://doi.org/10.1016/s0140-6736\(94\)90067-1](https://doi.org/10.1016/s0140-6736(94)90067-1)
- Steinberg-Yfrach, G., Rigaud, J.-L., Durantini, E. N., Moore, A. L., Gust, D., & Moore, T. A. (1998). Light-driven production of ATP catalysed by F₀F₁-ATP synthase in an artificial photosynthetic membrane. *Nature*, *392*, 479–482. <https://doi.org/10.1038/33116>
- Sun, S., Li, M., Dong, F., Wang, S., Tian, L., & Mann, S. (2016). Chemical signaling and functional activation in colloidosome-based protocells. *Small*, *12*(14), 1920–1927. <https://doi.org/10.1002/sml.201600243>
- Sun, Y., Ma, X., Zhou, D., Vacek, I., & Sun, A. M. (1996). Normalization of diabetes in spontaneously diabetic cynomolgus monkeys by xenografts of microencapsulated porcine islets without immunosuppression. *Journal of Clinical Investigation*, *98*, 1417–1422. <https://doi.org/10.1172/jci118929>
- Sun, Z. Z., Hayes, C. A., Shin, J., Caschera, F., Murray, R. M., & Noireaux, V. (2013). Protocols for implementing an Escherichia Coli based TX-TL cell-free expression system for synthetic biology. *Journal of Visualized Experiments: JoVE*, *79*(September), e50762. <https://doi.org/10.3791/50762>
- Ta, T., Bartolak-Suki, E., Park, E.-J., Karrobi, K., McDannold, N. J., & Porter, T. M. (2014). Localized delivery of doxorubicin in vivo from polymer-modified thermosensitive liposomes with MR-guided focused ultrasound-mediated heating. *Journal of Controlled Release*, *194* (November), 71–81. <https://doi.org/10.1016/j.jconrel.2014.08.013>

- Tagami, T., Ernsting, M. J., & Li, S.-D. (2011). Optimization of a novel and improved thermosensitive liposome formulated with DPPC and a Brij surfactant using a robust in vitro system. *Journal of Controlled Release*, 154, 290–297. <https://doi.org/10.1016/j.jconrel.2011.05.020>
- Tang, J., Shen, D., Caranasos, T. G., Wang, Z., Vandergriff, A. C., Allen, T. A., Hensley, M. T., Dinh, P.-U., Cores, J., Li, T.-S., Zhang, J., Kan, Q., & Cheng, K. (2017). Therapeutic microparticles functionalized with biomimetic cardiac stem cell membranes and secretome. *Nature Communications*, 8(January), 13724. <https://doi.org/10.1038/ncomms13724>
- Tang, T.-Y. D., Cecchi, D., Fracasso, G., Accardi, D., Coutable-Pennarun, A., Mansy, S. S., Perriman, A. W., Ross Anderson, J. L., & Mann, S. (2018). Gene-mediated chemical communication in synthetic protocell communities. *ACS Synthetic Biology*, 7(2), 339–346. <https://doi.org/10.1021/acssynbio.7b00306>
- Thamphiwatana, S., Gao, W., Pornpattananangkul, D., Zhang, Q., Victoria, F., Li, J., Li, J., Obonyo, M., & Zhang, L. (2014). Phospholipase A2-responsive antibiotic delivery via nanoparticle-stabilized liposomes for the treatment of bacterial infection. *Journal of Materials Chemistry. B, Materials for Biology and Medicine*, 2(46), 8201–8207. <https://doi.org/10.1039/C4TB01110D>
- Thompson, K. L., Williams, M., & Armes, S. P. (2015). Colloidosomes: Synthesis, properties and applications. *Journal of Colloid and Interface Science*, 447(June), 217–228. <https://doi.org/10.1016/j.jcis.2014.11.058>
- Toda, S., Blauch, L. R., Tang, S. K. Y., Morsut, L., & Lim, W. A. (2018). Programming self-organizing multicellular structures with synthetic cell-cell signaling. *Science*, 361(6398), 156–162. <https://doi.org/10.1126/science.aat0271>
- Torchilin, V. P. (2014). Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. *Nature Reviews. Drug Discovery*, 13(11), 813–827. <https://doi.org/10.1038/nrd4333>
- Tran, T. H., Nguyen, H. T., Van Le, N., Tran, T. T. P., Lee, J. S., Sae Kwang, K., Choi, H.-G., Yong, C. S., & Kim, J. O. (2017). Engineering of multifunctional temperature-sensitive liposomes for synergistic photothermal, photodynamic, and chemotherapeutic effects. *International Journal of Pharmaceutics*, 528(1–2), 692–704. <https://doi.org/10.1016/j.ijpharm.2017.06.069>
- Uyeda, A., Nakayama, S., Kato, Y., Watanabe, H., & Matsuura, T. (2016). Construction of an in vitro gene screening system of the E. Coli EmrE transporter using liposome display. *Analytical Chemistry*, 88, 12028–12035. <https://doi.org/10.1021/acs.analchem.6b02308>
- Villar, G., Graham, A. D., & Bayley, H. (2013). A tissue-like printed material. *Science*, 340(6128), 48–52. <https://doi.org/10.1126/science.1229495>
- Vu, V. P., Gifford, G. B., Chen, F., Benasutti, H., Wang, G., Groman, E. V., Scheinman, R., Saba, L., Moghimi, S. M., & Simberg, D. (2019). Immunoglobulin deposition on biomolecule corona determines complement opsonization efficiency of preclinical and clinical nanoparticles. *Nature Nanotechnology*, 14, 260–268. <https://doi.org/10.1038/s41565-018-0344-3>
- Wan, X., Zhang, S., Wang, F., Fan, W., Wu, C., Mao, K., Wang, H., Hu, Z., Yang, Y.-G., & Sun, T. (2018). Red blood cell-derived nanovesicles for safe and efficient macrophage-targeted drug delivery in vivo. *Biomaterials Science*, 7(1), 187–195. <https://doi.org/10.1039/c8bm01258j>
- Wang, J., Jelle Toebes, B., Plachokova, A. S., Liu, Q., Deng, D., Jansen, J. A., Yang, F., & Wilson, D. A. (2020). Self-propelled PLGA micro-motor with chemotactic response to inflammation. *Advanced Healthcare Materials*, 9, 1901710. <https://doi.org/10.1002/adhm.201901710>
- Wang, Y., Uchida, M., Waghvani, H. K., & Douglas, T. (2020). Synthetic virus-like particles for glutathione biosynthesis. *ACS Synthetic Biology*, 9(November), 3298–3310. <https://doi.org/10.1021/acssynbio.0c00368>
- Webb, C., Forbes, N., Roces, C. B., Anderluzzi, G., Lou, G., Abraham, S., Ingalls, L., Marshall, K., Leaver, T. J., Watts, J. A., Aylott, J. W., & Perrie, Y. (2020). Using microfluidics for scalable manufacturing of nanomedicines from bench to GMP: A case study using protein-loaded liposomes. *International Journal of Pharmaceutics*, 582(May), 119266. <https://doi.org/10.1016/j.ijpharm.2020.119266>
- Weiss, M., Frohnmayer, J. P., Benk, L. T., Haller, B., Janiesch, J.-W., Heitkamp, T., Börsch, M., Lira, R. B., Dimova, R., Lipowsky, R., Bodenschatz, E., Baret, J.-C., Vidakovic-Koch, T., Sundmacher, K., Platzman, I., & Spatz, J. P. (2018). Sequential bottom-up assembly of mechanically stabilized synthetic cells by microfluidics. *Nature Materials*, 17(1), 89–96. <https://doi.org/10.1038/nmat5005>
- Whitmire, D. R., Chambers, R. P., & Dillon, A. R. (1991). Multi-enzyme catalyzed rapid ethanol lowering in vitro. *Alcoholism, Clinical and Experimental Research*, 15(5), 804–807. <https://doi.org/10.1111/j.1530-0277.1991.tb00604.x>
- Witzigmann, D., Kulkarni, J. A., Leung, J., Chen, S., Cullis, P. R., & van der Meel, R. (2020). Lipid nanoparticle technology for therapeutic gene regulation in the liver. *Advanced Drug Delivery Reviews*, 159(July), 344–363. <https://doi.org/10.1016/j.addr.2020.06.026>
- Wu, Y., Liang, M., Cheley, S., Bayley, H., Cui, Q., & Chapman, E. R. (2011). Permeation of Styryl dyes through nanometer-scale pores in membranes. *Biochemistry*, 50(35), 7493–7502. <https://doi.org/10.1021/bi2006288>
- Xi, L., Li, C., Wang, Y., Gong, Y., Feng, S., & Li, S. (2020). Novel thermosensitive polymer-modified liposomes as nano-carrier of hydrophobic antitumor drugs. *Journal of Pharmaceutical Sciences*, 109(8), 2544–2552. <https://doi.org/10.1016/j.xphs.2020.05.006>
- Xie, Z., Yixue, S., Kim, G. B., Selvi, E., Ma, C., Aragon-Sanabria, V., Hsieh, J.-T., Cheng, D., & Yang, J. (2017). Immune cell-mediated biodegradable theranostic nanoparticles for melanoma targeting and drug delivery. *Small*, 13(10), 1603121. <https://doi.org/10.1002/smll.201603121>
- Xu, P., Zuo, H., Zhou, R., Wang, F., Xu, L., Ouyang, J., & Chen, B. (2017). Doxorubicin-loaded platelets conjugated with anti-CD22 mAbs: A novel targeted delivery system for lymphoma treatment with cardiopulmonary avoidance. *Oncotarget*, 8(35), 58322–58337. <https://doi.org/10.18632/oncotarget.16871>
- Xu, W., Wang, J., Rothman, J. E., & Pincet, F. (2015). Accelerating SNARE-mediated membrane fusion by DNA-lipid tethers. *Angewandte Chemie*, 54(48), 14388–14392. <https://doi.org/10.1002/anie.201506844>
- Yanagisawa, M., Iwamoto, M., Kato, A., Yoshikawa, K., & Oiki, S. (2011). Oriented reconstitution of a membrane protein in a giant unilamellar vesicle: Experimental verification with the potassium channel KcsA. *Journal of the American Chemical Society*, 133, 11774–11779. <https://doi.org/10.1021/ja2040859>

- Yarosh, D., Klein, J., Kibitel, J., Alas, L., O'Connor, A., Cummings, B., Grob, D., Gerstein, D., Gilchrest, B. A., Ichihashi, M., Ogoshi, M., Ueda, M., Fernandez, V., & Chadwick, C. (1996). Enzyme therapy of xeroderma pigmentosum: Safety and efficacy testing of T4N5 liposome lotion containing a prokaryotic DNA repair enzyme. *Photodermatology, Photoimmunology & Photomedicine*, *12*(3), 122–130. <https://doi.org/10.1111/j.1600-0781.1996.tb00188.x>
- Yarosh, D. B., Rosenthal, A., & Moy, R. (2019). Six critical questions for DNA repair enzymes in skincare products: A review in dialog. *Clinical, Cosmetic and Investigational Dermatology*, *12*(August), 617–624. <https://doi.org/10.2147/CCID.S220741>
- Yatvin, M. B., Weinstein, J. N., Dennis, W. H., & Blumenthal, R. (1978). Design of liposomes for enhanced local release of drugs by hyperthermia. *Science*, *202*(4374), 1290–1293. <https://doi.org/10.1126/science.364652>
- Yin, L., Chen, Y., Zhang, Z., Yin, Q., Zheng, N., & Cheng, J. (2015). Biodegradable micelles capable of mannose-mediated targeted drug delivery to cancer cells. *Macromolecular Rapid Communications*, *36*, 483–489. <https://doi.org/10.1002/marc.201400650>
- Yin, X., Chi, Y., Guo, C., Feng, S., Liu, J., Sun, K., & Zimei, W. (2017). Chitooligosaccharides modified reduction-sensitive liposomes: Enhanced cytoplasmic drug delivery and osteosarcomas-tumor inhibition in animal models. *Pharmaceutical Research*, *34*(10), 2172–2184. <https://doi.org/10.1007/s11095-017-2225-0>
- Zahednezhad, F., Saadat, M., Valizadeh, H., Zakeri-Milani, P., & Baradaran, B. (2019). Liposome and immune system interplay: Challenges and potentials. *Journal of Controlled Release: Official Journal of the Controlled Release Society*, *305*(July), 194–209. <https://doi.org/10.1016/j.jconrel.2019.05.030>
- Zawada, J. F., Yin, G., Steiner, A. R., Yang, J., Naresh, A., Roy, S. M., Gold, D. S., Heinsohn, H. G., & Murray, C. J. (2011). Microscale to manufacturing scale-up of cell-free cytokine production—a new approach for shortening protein production development timelines. *Biotechnology and Bioengineering*, *108*(7), 1570–1578. <https://doi.org/10.1002/bit.23103>
- Zhang, H. (2017). Thin-film hydration followed by extrusion method for liposome preparation. In G. G. M. D'Souza (Ed.), *Liposomes: Methods and protocols* (pp. 17–22). Springer New York. https://doi.org/10.1007/978-1-4939-6591-5_2
- Zhang, L., Guo, W., & Yuan, L. (2020). Advances in cell-free biosensors: Principle, mechanism, and applications. *Biotechnology Journal*, *15*, 2000187. <https://doi.org/10.1002/biot.202000187>
- Zhang, P., Yang, J., Cho, E., & Yuan, L. (2020). Bringing light into cell-free expression. *ACS Synthetic Biology*, *9*(8), 2144–2153. <https://doi.org/10.1021/acssynbio.0c00211>
- Zhang, R., Song, X., Liang, C., Yi, X., Song, G., Chao, Y., Yang, Y., Yang, K., Feng, L., & Liu, Z. (2017). Catalase-loaded cisplatin-prodrug-constructed liposomes to overcome tumor hypoxia for enhanced chemo-radiotherapy of cancer. *Biomaterials*, *138*, 13–21. <https://doi.org/10.1016/j.biomaterials.2017.05.025>

How to cite this article: Sato, W., Zajkowski, T., Moser, F., & Adamala, K. P. (2021). Synthetic cells in biomedical applications. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*, e1761. <https://doi.org/10.1002/wnan.1761>